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1GENERAL 
INTRODUCTION
Magnetic resonance imaging
In the history of brain tumor surgery, a few decades ago plain X-ray and angiography were the only 
imaging technologies available to the neurosurgeon. A brain tumor could be recognized by its “tumor 
blush”, which refers to the vascular abnormalities associated with the tumor. About thirty years ago, 
computed tomography (CT) and magnetic resonance imaging (MRI) were introduced in patient care. 
Whereas CT is superior is displaying bony structures, MRI is superior in displaying soft tissue - a 
huge benefit for brain tumor imaging. Such images are available as so-called slices, which give a two-
dimensional orientation towards the brain. 
In the operating room the neurosurgeon needs to “translate” the two-dimensional MRI pictures into a 
three-dimensional representation of the brain tumor and the surrounding structures. To assist the  
neurosurgeon in this process, a technique called “neuronavigation” has been introduced in the 
1990’s. To some extent this is comparable to a modern car navigation system: an MRI scan is made 
before surgery (the “roadmap”), and imported in the computer. In the operating room the neurosur-
geon needs to instruct the computer how the patient is positioned on the operating table, and then a 
dedicated pointer (optical wand) can be moved over the head of the patient while the computer 
screen shows the underlying brain structures. This gives a more threedimensional orientation which 
helps the neurosurgeon to prepare for surgery and to optimize the surgical approach. 
While this method is very useful for the planning of the surgical approach, it is less useful during the 
surgical procedure itself. As with a car navigation system, changes to the roadmap reduce the accu-
racy of the result. Such changes frequently happen during neurosurgical procedures: besides tumor 
resection also loss of cerebrospinal fluid and tissue edema contribute to anatomical changes that are 
not reflected on preoperative MRI. This phenomenon is referred to as “brain shift”. To compensate for 
brain shift, several research groups have worked on new technology to update the “roadmap” to re-
flect changes that occur during surgery due to brain shift. This new technology is referred to as  
“intraoperative MRI” (iMRI). 
INTRODUCTION
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iMRI
Every magnet has a so-called field strength, expressed in Tesla (T). Regular diagnostic MRI as cur-
rently used in hospitals works with 1.5T or 3T. When iMRI was introduced, iMRI devices worked with 
field strengths between 0.2T and 0.5T.[1,7,9] This is now referred to as “low-field strength” iMRI. The 
first commercially available iMRI system consisted of two vertically places magnets, and a neurosur-
geon working in between of them. Because of its physical appearance, this system from General Elec-
tric was referred to as the “double doughnut”. 
Afterwards, development of this technology went into two directions: either the system was optimized 
for workplace integration, or the system was optimized for image quality. 
This lead to the development of “(ultra) low-field strength” devices (between 0.12T and 0.5T) and 
“high-field strength” iMRI devices (1.5T or 3T).[2,5,4,6,8,3] The goal of the (ultra) low-field strength de-
vices was to support integration in the regular surgical workflow and cost-effectiveness, whereas the 
goal of high-field strength devices was to support optimal image quality and multimodality imaging 
(functional MRI, diffusion tensor imaging, magnetic resonance spectroscopy). The Maastricht Univer-
sity Medical Center works with a PoleStar N20 iMRI system (0.15T), shown in Figure 1.1. 
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Figure 1.1: PoleStar N20 (0.15 Tesla) intraoperative MRI
This ultra low-field strength iMRI system consists of two vertically placed permanent magnets that are 
lowered during surgery and raised during scanning (Figure 1.2). 
Figure 1.2: PoleStar during surgery (left) and during scanning (right)
The distance between both magnets is 27 centimeters and the field of view is 20 x 16 centimeters. Al-
though this is sufficient for patient positioning it does require extra considerations on how to place the 
headclamp. The MR signal is measured by a coil which is placed over the head of the patient (Figure 
1.3). 
Figure 1.3: The (signal receiving) coil is placed over the head of the patient.
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In order to measure the iMRI signal, radiofrequency signals coming from other sources than the mag-
net must be absent as much as possible. This so-called shielding is done by a Faraday cage. Most 
(i)MRI suites have shielded room, which means that the Faraday cage is integrated in the walls of the 
(i)MRI suite. With the ultra low-field strength iMRI device it is also possible to use “local shielding” by 
means of a tent that encloses the patient during scanning (the StarShield®). This is shown in Figure 
1.4. 
Figure 1.4: The StarShield® during scanning
When the system is not in use, it can be stored in a dedicated storage cabinet (Figure 1.5). In that 
case, the operating room can be used as a regular operating room without any magnetic  
interference. 
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Figure 1.5: The iMRI system in the storage cabinet
Brain tumors
Several sorts of brain tumors may benefit from iMRI-guided treatment, of which gliomas and pituitary 
adenomas are the most common. Regardless of which technology is used, the overall aim is to  
optimize the extent of tumor resection (EOTR) without causing (additional) neurologic deficit. This is 
particularly true for gliomas, based on a growing body of scientific literature that increased EOTR is 
associated with prolonged survival. Many papers were published in scientific journals claiming the 
added value of iMRI with respect to EOTR, but a systematic review of the literature had not yet been 
performed. 
Aim of this thesis
For this thesis the focus is on glioblastoma, the most aggressive subtype of the glioma tumor family. 
The median survival for a glioblastoma is 14.6 months after radiotherapy and chemotherapy with  
temozolomide. The central question of this thesis is whether iMRI-guided surgery is more beneficial 
for patients with a glioblastoma than the standard therapy (conventional neuronavigation-guided  
surgery). 
In chapter 2, a systematic review is performed to evaluate the existing literature on the topic. This  
systematic review was published in 2011 in Lancet Oncology, and demonstrates several sorts of bias 
in the literature that was published to date. In the same issue, the first randomized controlled trial on 
this topic was published by Senft et al. The results and conclusions of this randomized trial are  
discussed in chapter 5 and chapter 6. 
In chapter 3, the intraobserver and interobserver agreement of tumor volumetry is analyzed. Tumor 
volumetry is a common endpoint in recent neurosurgical studies that evaluate the effect of EOTR on 
patient outcome, but it has never been validated. 
 
In chapter 4, the correlation between contrast enhancement on iMRI and presence of tumor tissue on 
histology is evaluated. The rationale behind removal of contrast enhancing tissue as visible on (i)MRI 
is that this correlates to tumor presence. This has never systematically been analyzed for iMRI, and 
iatrogenic damage to the blood-brain barrier might cause a different enhancement pattern compared 
to preoperative (diagnostic) MRI. 
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In chapter 5, the results of our international multi-center randomized controlled trial are presented. 
The primary endpoint is EOTR based on preoperative and postoperative imaging. Secondary  
endpoints focus on clinical performance, health-related quality of life and survival. The results,  
conclusions, and differences compared to the Senft study are discussed. 
In chapter 6 a discussion is presented that combines all topics from the previous chapters, that  
evaluates the current level of scientific evidence for the central question in the thesis, and that offers 
suggestions for future research. 
7
Part of the research work presented in this PhD thesis (chapter 4 and chapter 5) has been supported 
by Medtronic Navigation  by means of an unrestricted grant. Medtronic Navigation was not involved 
in writing the related study protocols, had no access to the data, was not involved in writing the  
manuscripts and had no veto right for submission. 
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SYSTEMATIC 
REVIEW
Intraoperative MRI (iMRI)-guided intracranial surgery has been introduced more than a decade 
ago.[4] Starting at 0.5 Tesla (T) with the so-called “double doughnut” system, iMRI systems evolved 
into two directions: (ultra) low-field strength iMRI and high-field strength iMRI. Generally low-field 
strength refers to iMRI systems of 0.5T or less, and ultra low-field specifically refers to iMRI systems 
of less than 0.2T. High-field strength systems started at 1.5T but also 3T systems are in use. The bal-
ance between low-field and high-field strength systems mainly depends on a choice between  
required image quality, available imaging modalities, integration in the existing workflow, and cost. 
The main rationale for use of iMRI is intraoperative resection control. During surgery, the brain  
parenchyma gets distorted due to loss of cerebrospinal fluid, edema and tumor resection. This  
phenomenon is referred to as “brain shift”. As a consequence, using preoperative MRI for conven-
tional neuronavigation (cNN) becomes less reliable during surgery. Intraoperative imaging can  
update the source images that are used for neuronavigation. For visualization of brain parenchyma, 
images are preferably acquired using MRI. Therefore iMRI is useful: (1) to update neuronavigation  
information, and (2) to visualize remaining contrast enhancing tissue, suspect to be tumor. Frequently 
reported indications for iMRI-guided surgery are intra-axial tumors[3,8,22,40,45,44,48,51,52,54,61] 
and pituitary adenomas.[45,48,54,6,9,46,49,56,12] 
Since the introduction of iMRI, many papers have reported about the (added) value of iMRI-guided 
surgery.[3,8,22,40,42,44,48,51,52,5,56,13,16,14,15,17,24,28,39,38] However, to the best of our  
knowledge no systematic review on this topic has been published yet. As iMRI-guided surgery  
requires expensive equipment and prolongs the time of surgery, justification for widespread use 
should preferably be based on evidence. We conducted a systematic review of the literature in line 
with the PRISMA Statement.[30] As various types of pathology require different surgical strategies, 
we decided to focus on high grade gliomas in general, and glioblastomas in particular. The objective 
is to address the added value of iMRI-guided resection of glioblastoma compared to cNN-guided  
resection with respect to extent of tumor resection (EOTR), quality of life, and survival. 
INTRODUCTION
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Research protocol
Our review protocol consisted of the detailed research question, the search strategy, the screening 
criteria for titles and abstracts, and the screening criteria for full-text articles. The detailed research 
question was structured using the so-called PICOS approach (Patient, Intervention, Comparator,  
Outcome, Study design). Our PICOS research question was formulated as follows: is iMRI-guided  
tumor resection in adults with glioblastoma more effective than cNN-guided resection with respect to 
EOTR, quality of life, and survival, as published in randomized controlled trials and cohort studies? 
Search databases were MEDLINE (using PubMed), EMBASE (using OVID), the Cochrane Library and 
ClinicalTrials.gov. Search queries were optimized for each specific database. 
After deleting duplicate records, titles and abstracts were screened and included if they represented 
randomized or cohort studies on patients with glioblastoma or high grade glioma who received neuro-
surgical intervention using iMRI. Studies that specifically reported on a pediatric population or fo-
cused on radiosurgery, radiotherapy or chemotherapy were excluded at this point. Of the remaining 
records full-text articles were assessed according to the same criteria, with one additional inclusion 
criterion (quantitative information on added value of iMRI) and with one additional exclusion criterion 
(overlapping data). A spreadsheet contained all data collection items for the full-text versions of  
included articles (reflected in Tables 2.2-2.4). The research protocol has been set up by the first and 
last author (PK, HvS) and searches were performed independently by the first two authors (PK, KtM). 
The last author served as an independent third reviewer in case differences in opinion between the 
two reviewers existed. 
Eligibility criteria and search strategy
The PICOS research question served as the foundation for study selection, without additional  
restrictions in publication date, length of follow-up, language or publication status. As iMRI is a fairly 
new technique, the topic itself will limit the publication dates. We used the previously mentioned data-
bases for searching. We decided to use MEDLINE / PubMed as our primary data source, and in-
cluded “glioma” as a medical subject heading (MeSH) to search with maximum sensitivity. Other data-
bases were used to find additional literature on glioblastomas or high grade gliomas (HGGs). Of 
these two only “glioblastomas” turned out to be a valid thesaurus term (EMBASE) or useful keyword 
(Cochrane Library). Full search strategies are detailed for each database in the next paragraph. 
METHODS
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The MEDLINE query with MeSH terms was: ("Magnetic Resonance Imaging, Interventional"[Mesh] OR 
"Surgery, Computer-Assisted"[Mesh] OR "Neuronavigation"[Mesh] OR "Therapy, Computer-
Assisted"[Mesh]) AND ("Glioma"[Mesh] OR "Glioblastoma"[Mesh]). The OVID query with thesaurus 
terms was: (“interventional magnetic resonance imaging” OR “computer assisted surgery” OR “neuro-
navigation”) AND (“glioblastoma”). The Cochrane Library query with keywords was: ((Magnetic  
Resonance Imaging, Interventional):kw or (neuronavigation):kw or (Surgery, Computer-Assisted):kw) 
and (glioblastoma):kw. The ClinicalTrials.gov query consisted of free text: (intraoperative mri OR inter-
ventional mri OR neuronavigation OR computer-assisted surgery) AND glioblastoma.
Study selection and data collection
After record screening full-text assessment of articles was performed for study selection. An  
additional inclusion criterion for full-text assessment was quantitative information on the added value 
of iMRI specific for glioblastoma or HGG. Added value was described as one or more of the PICOS 
outcome parameters. An additional exclusion criterion for full-text assessment was overlapping data 
from the same cohort in different studies. In this case, the study with the most specific information on 
glioblastoma or HGG was selected. 
Data collection was done in a prospectively designed questionnaire with Microsoft Excel (Microsoft 
Corporation, Redmond, WA). The data collection items were separated in three categories: study  
design parameters (Table 2.2), iMRI parameters (Table 2.3) and study population and resection  
parameters (Table 2.4). No meta-analysis was planned as we did not expect that a valid quantitative 
data synthesis could be performed. Especially differences in the magnet’s field strength were thought 
to influence image quality and thus the results. 
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Study selection
Figure 2.1 represents the various stages in searching the literature and selecting studies for eligibility.
Figure 2.1: Flow diagram for literature assessment 
Database searching identified 670 records, and another 12 records were identified through other 
sources. After removing duplicates, 600 records were available for screening. Of these, 567 were  
excluded because they did not meet the selection criteria. After full-text assessment of the remaining 
33 articles, another 21 were excluded from the qualitative synthesis. The reasons for excluding  
articles after full-text assessment are displayed in Table 2.1. Three of these were only excluded after 
the independent assessment by a third reviewer, because the first two reviewers disagreed. These 
are marked with an asterisk in Table 2.1. The remaining 12 articles were used for qualitative  
synthesis. 
RESULTS
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Study characteristics
Twelve studies met our selection criteria: 2 prospective and 10 retrospective cohort studies. If the  
prospective or retrospective design was not specified in the full-text article, then it was assessed  
independently by both reviewers, who agreed in all cases. We did not find any randomized controlled 
trials (RCT) that met the selection criteria. Most studies offered descriptive statistics of a hetero-
geneous population, consisting of mixed pathology. Publication years were between 1999 and 2010. 
Most studies offered inclusion criteria for patient selection, and only two offered exclusion criteria. 
15
Table 2.1: Reasons for excluding articles after full-text assessment
Reference Reason for exclusion
Bergsneider, 2005 [2] No specific results for HGG or GBM
Black, 1999 [3] No specific data for HGG or GBM
Fuji, 2009 [10] Article in Japanese and no translator available
Ganslandt, 2002 [11] Focused on neuronavigation, and does not offer specific data on HGG 
or GBM
Jankovski, 2008 [20] No specific results for HGG or GBM
Lewin, 2007 [29] No specific data for HGG or GBM
Maesawa, 2009 [32] No specific data for HGG or GBM
McPherson, 2003 [34] No specific data for HGG or GBM
Nimsky, 2002 [45] Overlapping data with included study 38
Nimsky, 2003 [37] Overlapping data with included study 34
Nimsky, 2004 [40] * Overlapping data with included study 34
Nimsky, 2004 [44] Overlapping data with included study 34
Nimsky, 2009 [47] * Focused on accuracy of updating neuronavigation
Ram, 2003 [50] No specific data for HGG or GBM
Schulder, 2001 [53] No specific data for HGG or GBM
Schulder, 2006 [54] No specific data for HGG or GBM
Schulder, 2009 [55] No specific data for HGG or GBM
Senft, 2008 [59] * Overlapping data with included study 41
Senft, 2010 [58] Overlapping data with included study 41
Trantakis, 2003 [63] Overlapping data with included study 10
Yrjänä, 2007 [66] No specific data for HGG or GBM
Abbreviations: GBM = Glioblastoma Multiforme, HGG = High Grade Glioma.
Articles marked with asterisk (*) were only excluded after full-text assessment by an independent 
third reviewer.
Mostly the description of the study population was in general terms, like “all gliomas” operated in a 
certain time frame. Most studies offered data on EOTR, although this was measured in different ways. 
All studies offered information on the iMRI system that was used, including field strength of the  
magnet and MR sequences used during surgery. Information on used contrast agent was more  
limited, and mentioned in 8 out of 12 studies.[7,27,41,58] Only 3 out of 12 studies explicitly  
mentioned the cumulative additional time spent in the operating room when iMRI was used.[22,7,19] 
This cannot indirectly be calculated from the scanning time itself, as a longer preparation time before 
incision and longer preparation times before and immediately after scanning do need to be taken into 
account. 
10 out of 12 studies offered a description on how gross total resection (GTR) was defined. 7 out of 12 
studies described how the use of iMRI influenced EOTR and helped in achieving GTR. Only 2 out of 
12 studies also explicitly stated in how many patients GTR was intended. 
Outcome parameters were often mentioned without stratification for the various pathological diagno-
ses. Survival data were available in 4 out of 12 studies, comparing GTR to subtotal resection or iMRI-
guided surgery to cNN-guided surgery (non-randomized or matched control group).[52,65,58,19] 
The detailed study design parameters for the selected studies are displayed in table 2.2. Table 2.3 
shows their iMRI parameters, and table 2.4 their study population and resection parameters. 
Results of individual studies
The focus of our search question was on HGG in general, and glioblastoma in particular. Therefore 
we extracted these data from the selected studies, even if the original studies analyzed a broader 
spectrum of pathology. In the next paragraphs we will highlight the most important messages of each 
selected study in alphabetical order, and information that was found to be missing and maybe  
influencing the conclusions. Details are available in Tables 2.2-2.4. 
Knauth et al (1999)[22] retrospectively analyzed 41 HGG cases (in 38 patients) on a 0.2 Tesla (T) 
scanner and double-dose (0.2 mmol/kg) of contrast agent. GTR was intended in all cases. On the 
first iMRI scan GTR was achieved in 37% of cases. The authors did not describe the results of the 
last iMRI scan, but mention that GTR was achieved in 76% of cases according to early postoperative 
MRI. Clinical performance was not specified. 
Wirtz et al (2000)[65] retrospectively analyzed 68 HGG cases (of which 62 had glioblastoma) on a 
0.2T scanner and a double-dose of contrast agent. Scans were made directly and 5, 10 and 20  
16
minutes after contrast administration. GTR was defined as removal of contrast enhancement as visi-
ble on T1-weighted MRI. On the first iMRI scan GTR was achieved in 27% of HGG cases and in 67% 
of cases resection was continued based on the iMRI scan. The authors did not describe the results of 
the last iMRI scan, and do not mention the number of HGG cases where GTR was intended. Median 
survival was 13.3 months for the GTR cases compared to 9.2 months for the STR cases (p=0.0035). 
Clinical performance was not specified for the HGG or glioblastoma subpopulation. 
Bohinski et al (2001)[5] prospectively analyzed their results with 30 HGG patients on a 0.3T iMRI 
scanner and single-dose (0.1 mmol/kg) of contrast agent. In 60% of HGG patients iMRI lead to addi-
tional resection. The authors did not describe the number of HGG patients in which gross total resec-
tion (GTR) was intended, nor the results of the last iMRI scan. Clinical performance was not specified 
for the HGG subpopulation. 
Nimsky et al (2003, 2006)[36,41] analyzed 32 glioblastoma cases on a 0.2T scanner with a single-
dose of contrast agent administered just prior to scanning, and 57 glioblastoma cases on a 1.5T 
scanner with a single-dose of contrast agent as well. On the 0.2T scanner GTR was achieved in 6/32 
cases on the first iMRI scan, and in 7/32 cases on the last iMRI scan. The number of intended GTRs 
was not specified for this group. On the 1.5T scanner GTR was achieved in 16/57 cases on the first 
iMRI scan and in 23/57 cases on the last iMRI scan. Although the number of intended GTRs was not 
specified for this group either, from the text could be derived that GTR was not intended in at least 
25/57 cases. It should be noted that the authors performed a smaller study on volumetric assessment 
of glioma removal (excluded for overlapping data) by applying manual segmentation on a dedicated 
workstation, using co-registration of all imaging data sets. The authors reported a mean additional  
resection of 12% in intended subtotal resection cases, and a mean additional resection of 20% in  
intended GTR cases. Clinical performance was not specified for the glioblastoma subpopulation.
Hirschberg et al (2005)[19] retrospectively analyzed 32 glioblastoma cases (of which 27 were eligible 
for further analysis) on a 0.5T iMRI scanner. Although the number of cases in which GTR is intended 
is not explicitly specified, this seems to be 19/27 cases (derived from text). On the first iMRI GTR is 
achieved in 5/27 cases. The authors did not provide data for the last iMRI scan. Contrast agent was 
not specified in the text, nor its dose. Median survival in the iMRI group was 14.5 months compared 
to 12.1 months for a matched control group. This difference was not statistically significant (p=0,14). 
Clinical performance improved in 16% of cases, remained unchanged in 55% and deteriorated in 
29%. 
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Schneider et al (2005)[52] retrospectively analyzed 31 primary glioblastoma cases on a 0.5T scanner 
with a single-dose of contrast agent immediate before scanning and 4 hours afterwards if a new iMRI 
scan was required. EOTR was assessed volumetrically and GTR was defined as >95% removal of the 
contrast-enhancing mass (including necrosis) on T1-weighted MRI. GTR was achieved in 2/31 pa-
tients on the first iMRI scan and in 11/31 patients on the last iMRI scan. The number of intended 
GTRs was not specified. The authors describe a median survival of 537 days for GTR compared to 
237 days for subtotal resection (STR; p=0.004). There were no further volumetric data of the EOTR for 
the STR group, so all EOTR <95% were represented. Clinical performance deteriorated in 13% of pa-
tients.
Busse et al (2006)[7] retrospectively analyzed 24 glioblastoma cases on a 0.5T iMRI scanner, leading 
to a “total” resection on the last iMRI scan in 4/24 patients according to consensus between the  
neuroradiologist and the neurosurgeon. The authors did not provide any information on the first iMRI 
scan and the contrast dose. Clinical performance was not specified for the glioblastoma subpopula-
tion. The authors mainly evaluated their results to compare real-time reformatted iMRI scans with suc-
cessive iMRI scans. We did not use that stratification in this review. 
Muragaki (2006)[35] et al retrospectively analyzed 30 glioblastoma cases on a 0.3T scanner. They 
used a double-dose of contrast agent for their most recent cases, and a single-dose for the earlier 
ones. They used manual segmentation to measure the EOTR volumetrically, defined as removal of 
contrast-enhancing tissue as visible on T1-weighted MRI. At the last iMRI scan in 90% EOTR was 
achieved. They did neither provide details on the number of intended GTRs, nor on the results on the 
first iMRI scan. Also the different doses of contrast agent may influence the results for EOTR. Clinical 
performance was not specified for the glioblastoma subpopulation.
Hatiboglu et al (2009)[18] prospectively analyzed 27 glioblastoma cases on a 1.5T scanner with a 
single-dose of contrast agent. EOTR was assessed with volumetry, and GTR was defined as >95% 
EOTR on contrast-enhanced T1-weighted MRI. Manual segmentation was performed by 2 neuro-
surgeons, and according to the authors their technique was equivalent when they were tested for  
variability in their determinations. No specification was provided whether this only concerned segmen-
tation on preoperative images, or on postoperative images as well. The first iMRI scan showed GTR 
in 12/27 patients, and the last iMRI scan in 24/27 patients. The authors selected patients with tumors 
near eloquent areas, but did not explicitly describe in what number of patients GTR was intended. 
Clinical performance was not specified for the glioblastoma subpopulation.
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Lenaburg et al (2009)[27] retrospectively analyzed 35 glioblastoma cases (in 29 patients) on a 0.2T 
scanner. The first iMRI scan lead to further resection in 72% of cases, and the last iMRI scan showed 
a resection >95% in 27/35 cases. However, EOTR was calculated using a mathematical “sphere-
based” model. In our opinion, this cannot be used for postoperative imaging, which makes compari-
son with preoperative tumor volume unreliable. The authors did not provide information on contrast 
agent, and did not mention the number of cases in which GTR was intended. Clinical performance 
deteriorated in 1/35 patients. 
Senft et al (2010)[57] retrospectively analyzed 41 primary glioblastoma cases on a 0.15T scanner. 
GTR was intended in all cases. 10 glioblastoma cases were operated with iMRI and 31 were oper-
ated with cNN. GTR was defined as absence of contrast-enhancement on T1-weighted MRI. Postop-
erative MRI within 72 hours after surgery showed GTR in 10/10 iMRI cases and in 19/31 cNN cases. 
When related to EOTR, median survival was 74 weeks for the GTR group compared to 46 weeks for 
the STR group (p<0.001). When related to the treatment group, median survival was 88 weeks for the 
iMRI group compared to 68 weeks for the cNN group. However, the treatment group survival data 
were not statistically significant (p=0.07). Treatment group allocation was not randomized, therefore 
selection bias could be present in this study. Further no information was available on the contrast 
agent that was used. Clinical performance was not specified. 
19
20
Table 2.2: Study design parameters of included studies
Reference Type Inclusion criteria Exclusion criteria Time frame
Knauth, 1999 [22] R HGG NS NS
Wirtz, 2000 [65] R supratentorial glioma; IC NS NS (“from Dec 
1995” until 
maximally Aug 
1999)
Bohinski, 2001 [5] P primary and recurrent 
supratentorial glioma WHO 
grade 2, 3,4; age ≥ 18y; IC
NS May 1998 – Oct 
1999
Nimsky, 2003 [36] R supratentorial glioma NS Mar 1996 – Jul 
2001
Hirschberg, 2005 [19] R GBM with follow-up ≥ 2m NS Jan 1999 – Jun 
2002
Schneider, 2005 [52] R supratentorial GBM confirmed 
by 2 neuropathologists; no 
recurrent tumor; age ≥ 18y; 
preoperative KPS ≥ 70; ASA 
class 1 or 2; IC
NS Sep 1997 – Jan 
2002
Busse, 2006 [7] R 95 cases of 3 neurosurgeons 
who all did ≥ 10 iMRI 
surgeries; IC
NS NS (3,5y 
timeframe)
Muragaki, 2006 [35] R intracranial glioma surgery 
with iMRI; IC
NS Jul 2000 – Jul 2004
Nimsky, 2006 [41] R glioma; IC NS Apr 2002 – Aug 
2005
Hatiboglu, 2009 [18] P large, infiltrative or within/near 
eloquent areas located 
gliomas; IC
No postoperative 
MRI
Sep 2006 – Aug 
2007
Lenaburg, 2009 [27] R GBM; IC NS Jul 2002 – Jul 2006
Senft, 2010 [57] R primary GBM, histologically 
confirmed; intended GTR; KPS 
≥ 70; IC
recurrent tumor, 
intended STR, 
biopsies
Jul 2004 – Dec 
2005
Table 2.2 (continued): Study design parameters of included studies
Reference Primary endpoint Primary endpoint measurement
Knauth, 1999 [22] CE on iMRI and EPMRI NS
Wirtz, 2000 [65] EOTR scan interpretation
Bohinski, 2001 [5] EOTR interpretation by neuroradiologist
Nimsky, 2003 [36] NS (“our experience”) N/A
Hirschberg, 2005 [19] NS (“impact on procedure, 
outcome and median survival”)
(data analysis)
Schneider, 2005 [52] EOTR volumetry based on manual 
segmentation
Busse, 2006 [7] EOTR consensus neurosurgeon and 
neuroradiologist
Muragaki, 2006 [35] focus on functional outcome neurologic status and comorbidity
Nimsky, 2006 [41] NS (“the effects of iMRI and 
functional neuronavigation in 
glioma surgery”)
NS
Hatiboglu, 2009 [18] EOTR volumetric analysis on Vitrea 
workstation by 2 neurosurgeons
Lenaburg, 2009 [27] EOTR volumetry (sphere model)
Senft, 2010 [57] EOTR GTR defined as no residual CE on 
EPMRI, evaluated by 
neuroradiologist blinded for 
treatment modality
Abbreviations: ASA = American Society of Anaesthesiology, CE = Contrast Enhancement, EOTR = 
Extent Of Tumor Resection, EPMRI = Early Postoperative MRI, HGG = High Grade Glioma, GBM = 
Glioblastoma Multiforme, GTR = Gross Total Resection, IC = Informed Consent, iMRI = 
Intraoperative MRI, KPS = Karnofsky Performance Score, m = months, N/A = Not Applicable, NS 
= Not Specified, P = Prospective study, R = Retrospective study, STR = Subtotal Resection, y = 
years
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Table 2.3: Intraoperative MRI parameters of included studies
Reference T Contrast administration
Agent Dose Timing
Knauth, 1999 [22] 0,2 Gd-DTPA 0,2 mmol/kg NS
Wirtz, 2000 [65] 0,2 Gd-DTPA 0,2 mmol/kg scans 0, 5, 10 and 20m after 
contrast administration
Bohinski, 2001 [5] 0,3 gadodiamide 0,1 mmol/kg NS
Nimsky, 2003 [36] 0,2 Gd-DTPA 0,2 ml/kg just prior to scanning
Hirschberg, 2005 
[19]
0,5 gadolinium 
(NS)
NS NS
Schneider, 2005 
[52]
0,5 Gd-dimeg 0,1 mmol/kg before scanning and 4h afterwards 
(if new scan necessary)
Busse, 2006 [7] 0,5 NS NS NS
Muragaki, 2006 
[35]
0,3 Gd-DTPA 0,4 ml/kg
(0,2 ml/kg previously)
NS
Nimsky, 2006 [41] 1,5 Gd-DTPA* 0,2ml/kg* before scanning*
Hatiboglu, 2009 
[18]
1,5 Gd-dimeg 0,2 ml/kg NS
Lenaburg, 2009 
[27]
0,2 NS NS NS
Senft, 2010 [57] 0,15 NS NS NS
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Table 2.3 (continued): Intraoperative MRI parameters of included studies (continued)
Reference Scanning time iMRI sequences used Extra OR time
Knauth, 1999 [22] NS T1 1h for scanning and setup
Wirtz, 2000 [65] NS T1, T2, FLAIR NS
Bohinski, 2001 [5] mean total 16m T1, T2 NS
Nimsky, 2003 [36] NS T1, FLAIR, other NS
Hirschberg, 2005 [19] NS T1 1,6h
Schneider, 2005 [52] NS T1, T2, other NS
Busse, 2006 [7] NS T1, other 13m for “advanced navigation”
Muragaki, 2006 [35] NS T1, T2 NS
Nimsky, 2006 [41] circa 73m per 
procedure
T1, T2, FLAIR, other NS
Hatiboglu, 2009 [18] NS T1, T2, FLAIR, other NS
Lenaburg, 2009 [27] 13,5m average T1, T2 NS
Senft, 2010 [57] NS T1 NS
Abbreviations: FLAIR = Fluid Attenuated Inversion Recovery, Gd-dimeg = gadopentetate 
dimeglumine, Gd-DTPA = gadolinium Diethylene Triamine Pentaacetic Acid, h = hours, m = 
minutes, NS = Not Specified, OR = Operating Room, T = the magnet’s field strength in Tesla
* Derived from other study, which was excluded for overlapping data,(REF: Nimksy2004 beide) 
because the included study did not specify this information.
23
Table 2.4: Study population and resection parameters of included studies*
Reference Gross Total Resection
Definition Volumetry Intended 1st iMRI Last iMRI
Knauth, 
1999 [22]
NS No in 100% 37% not performed
(76% GTR on EPMRI)
Wirtz, 2000 
[65]
removal of CE on 
iMRI evaluated by 
neurosurgeon
No NS in 27% of HGG in 67% of HGG resection 
continued
(no final iMRI result 
available)
Bohinski, 
2001 [5]
opinion 
neuroradiologist 
and neurosurgeon
No NSSub 
(“in 30/40 
gliomas”)
additional 
resection in 
60% of HGG
NS
Nimsky, 
2003 [36]
evaluation (by 
neurosurgeon?)
No NSSub 6/32 pt 7/32 pt
Hirschberg
, 2005 [19]
opinion 
neurosurgeon and 
neuroradiologist
No NS
(seems to 
be19/27 
pt)
5/27 pt NS
Schneider, 
2005 [52]
>95% removal of 
CE (with necrosis) 
on T1Gd 
measured by 
segmentation
Yes: sum 
of tumor 
area per 
slice x 
slice 
thickness 
(+ gap 
thickness)
NS 2/31 pt 11/31 pt
Busse, 
2006 [7]
consensus 
neurosurgeon + 
neuroradiologist
No NS NS 4 GBM had “total” resection
Muragaki, 
2006 [35]
removal of CE on 
T1Gd measured 
by segmentation
Yes: sum 
of tumor 
area per 
slice x 
slice 
thickness
NS NS 90% EOTR
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Table 2.4 (continued): Study population and resection parameters of included studies*
Reference Gross Total Resection
Definition Volumetry Intended 1st iMRI Last iMRI
Nimsky, 
2006 [41]
NS No** at least 
not in 
25/57 pt
16/57 pt 23/57 pt
Hatiboglu, 
2009 [18]
>95% EOTR
(= CE onT1Gd)
Yes: tumor 
area on 
Vitrea by 2 
neurosurgeo
ns
NS 12/27 pt 24/27 pt
Lenaburg, 
2009 [27]
mathematical 
model
Yes: 4/3 x π 
x a x b x c 
(a, b and c 
are 
diameters)
NS NS (“in 72% 
further 
resection”)
27/35 cases had resection 
>95%
Senft, 2010 
[57]
no residual CE 
seen by 
neuroradiologist
(blinded for 
treatment group)
No in 100% NS 10/10 iMRI pt and 19/31 
cNN pt (on EPMRI)
Abbreviations: cNN = Conventional Neuronavigation, CE = Contrast Enhancement, CSF = 
Cerebrospinal Fluid, d = days, D = Deteriorated clinical performance, EOTR = Extent Of Tumor 
Resection, EPMRI = Early Postoperative MRI, GBM = Glioblastoma Multiforme, GTR = Gross Total 
Resection, HGG = High Grade Glioma, I = Improved clinical performance, incl rec = including 
recurrences, iMRI = Intraoperative MRI, m = months, NS = Not Specified, NSSub = Not Specified 
for this subpopulation (in contrast to total study cohort), pt = patients, STR = Subtotal Resection, 
T1Gd = T1-weighted MRI after gadolinium administration, U = unchanged clinical performance, vs 
= versus, w = weeks, / (forward slash) = “out of”
* If possible, only data on GBM were used (derived from text, tables or figures). If not available, 
data for HGG were used.
** In a smaller study on volumetric assessment of glioma removal (excluded for overlapping 
data) the authors performed volumetry by applying manual segmentation on the VectorVision 
workstation, using co-registration of all imaging data sets.
*** originally 32 GBMs were operated for this study, but only 27 were described to have good 
image quality and were used for further analysis
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Table 2.4 (continued): Study population and resection parameters of included studies*
Reference n Clinical 
performance
Complications Survival
Knauth, 1999 
[22]
41 HGG
in 38 pt
NS NS NS
Wirtz, 2000 
[65]
68 HGG
incl rec
(62 GBM)
NSSub NSSub median 13,3m for GTR vs 
9,2m for STR (p=0,0035)
Bohinski, 
2001 [5]
30 HGG NSSub NSSub NS
Nimsky, 2003 
[36]
32 GBM NSSub NSSub NS
Hirschberg, 
2005 [19]
32 
GBM***
I 16% U 55% D 
29%
2 infections
3 visual field defects
mean 14,5m vs 12,1m for 
matched control group 
without iMRI (p=0,14)
Schneider, 
2005 [52]
31 GBM D 13% 1 rebleed;1 edema; 
2 new paresis
median 537d for GTR vs 
237d for STR (p=0,004)
Busse, 2006 
[7]
24 GBM
incl rec
NSSub NSSub NS
Muragaki, 
2006 [35]
30 GBM NSSub NSSub NS
Nimsky, 2006 
[41]
57 GBM NSSub NSSub NS
Hatiboglu, 
2009 [18]
27 GBM NSSub NSSub NS
Lenaburg, 
2009 [27]
35 GBM
in 29 pt
D 1/35 cases 1 respiratory failure 
(died); 2 wound 
infections leading to 
wound revision’ 1 
CSF leak
NS
Senft, 2010 
[57]
41 GBM NS NS median 74w for GTR vs 46w 
for STR (p<0,001); 
88w for iMRI vs 68w for cNN 
(p=0,07)
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Summary of evidence
This review aims to provide a qualitative synthesis of the literature on the added value of iMRI-guided 
resection of glioblastoma compared to cNN with respect to EOTR, quality of life, and survival. Many 
studies have been published on this topic, but they suffer from serious limitations like heterogeneity in 
study populations and technical equipment, attribution bias, and different methods to assess EOTR. 
These and other limitations will be discussed in detail in the next paragraphs. 
Limitations
Population heterogeneity
Frequently study populations are very heterogeneous regarding to pathological diagnosis, and often 
outcome parameters are not stratified for this heterogeneity. Many papers are excluded in this review 
for that reason.[3,54,2,11,20,29,32,34,50,55,53,66] Even in a glioma subpopulation such stratification 
is mandatory. Different types and WHO grades differ significantly in macroscopical and sometimes 
MRI appearance, and survival. This influences outcome parameters related to iMRI-guided surgery. 
While the excluded papers can be very informative in providing background information on iMRI-
guided surgery, they can not be used to answer our search question. 
Overlapping data
The second most frequent reason to exclude papers for this review was overlapping patient 
data.[40,45,44,58,37,59,63] Multiple papers about the same cohort can offer valuable insights from 
various points of view. On the other hand, results for EOTR or survival can only be used once in data 
collection when performing a literature review. As a consequence of both population heterogeneity 
and overlapping data, the net amount of literature that contributes to establish evidence is limited. 
Attribution bias
Because patients with a high grade glioma have limited survival expectancy, the neurosurgeon is 
careful to avoid additional brain damage (“do no harm” principle). When the neurosurgeon is in doubt 
DISCUSSION
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about possible tumor remnants around the resection cavity, resection is stopped and an iMRI scan is 
made. In our experience iMRI-guided surgery leads to a more conservative resection before the first 
intraoperative control scan is made. From informal conversations we understood this situation is com-
parable in several other centers. 
This principle is important when interpreting studies on iMRI-guided resection. Often the conclusion 
is that an increased EOTR after intraoperative scanning is achieved. Bias arises when this increased 
EOTR is attributed to the use of iMRI. This refers to another principle: “post hoc ergo propter hoc?” 
(“after which, so because of?”). Without the availability of intraoperative resection control, the neuro-
surgeon might be more aggressive to prevent unintended postoperative tumor remnants or even a 
second procedure for additional resection. Therefore the effect of iMRI in increasing EOTR may be 
overestimated. It is unknown to what extent this attribution bias is related to the surgical and iMRI  
experience of the neurosurgeon. The only way to prevent this attribution bias is performing a  
randomized trial, which has not been done to date. 
Assessment of EOTR
In the 12 selected studies there are at least 5 different descriptions for GTR, if it is defined explicitly at 
all (Table 2.4). Essentially there are two approaches used: qualitative (presence of contrast enhance-
ment on T1-weighted MRI) or quantitative (volumetric assessment by manual segmentation). The first 
method is a rough method that dichotomizes GTR between “yes” and “no”. The second method has 
the theoretical advantage of a higher precision, but has an unacceptable low interobserver agree-
ment for postoperative images (intraclass correlation coefficient = 0.54) to serve as a valid method to 
assess EOTR.[25] The MacDonald criteria,[31] Response Evaluation Criteria In Solid Tumors (RE-
CIST)[62] and Response Assessment in Neuro-Oncology criteria (RANO)[64] are all not useful for 
postoperative tumor size assessment because they require an approximately spherical tumor. This is 
clearly not the case for contrast enhancement at the border of the resection cavity. Reliable and  
validated criteria to assess EOTR are necessary to compare the results of neurosurgical studies. In 
our opinion, an intraclass correlation coefficient of at least 0.8 is required to allow comparison of re-
sults between different studies. 
Different field strengths
Regarding iMRI a distinction is made between low-field strength (≤ 0.5 Tesla) and high-field strength 
(≥ 1.5 Tesla) devices. The field strength of an iMRI system is directly related to the spatial resolution 
of the images. Therefore, image quality on high-field strength devices is better than on low-field 
strength devices. This may influence the results, although the small number of studies included for 
this review showed no evidence for this. 
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Besides offering a higher spatial resolution, high-field strength systems are capable of offering  
several imaging modalities that are hard or pratically impossible to acquire on low-field strength  
systems. Acquisition of functional MR images has been reported on low-field strength systems,[1] but 
fiber tracking using Diffusion Tensor Imaging or MR spectroscopy has only been reported on high-
field strength MRI so far.[43] The possibility to use such additional imaging sequences in  
combination with higher spatial resolution has to be balanced against the significantly higher cost of 
purchasing and maintaining this equipment. The amount and type of iMRI surgeries that will be  
performed will be an important factor in these considerations, as well as the associated research  
opportunities and the possibilities for using a high-field strength system for diagnostic imaging in 
non-surgical cases. 
Contrast agent
The application of contrast agent differs between studies, and two parameters may be important: 
dose and timing. First, the required dose may be related to the magnet’s field strength. A so-called 
“double dose” of contrast agent (0.2 mmol/kg) for low-field strength scanning is said to be compara-
ble to a “single dose” (0.1 mmol/kg) for high-field strength scanning.[21] Second, the timing of con-
trast administration will influence the amount of residual enhancement. When contrast agent is admin-
istered at the beginning of surgery, a part will still be present when performing the first intra-operative 
scan. Variation in presence of residual contrast agent may lead to variation in contrast enhancement, 
which can be difficult to distinguish from residual tumor.[17,23] Recently it has been advocated to 
wait with contrast administration until the first intra-operative scan, to avoid confusion between  
residual and new contrast enhancement.[23] Especially earlier studies in which contrast agent was 
administered both before surgery and before the first resection control scan might overestimate the 
amount of tumor resection: part of the resected tissue will be this residual enhancement on the intra-
operative scan. Even though some authors sent the additionally resected tissue for separate  
histological diagnosis,[51,52,36,33] the “presence of tumor cells” does not exclude that more tissue 
has been resected than intended, based on the preoperative MRI. 
Quality of life and survival
Only 3 out of 12 studies provided explicit data on clinical performance, and no studies provided data 
on quality of life. This is an important topic that needs more attention in future studies. Increased 
EOTR should be weighed against clinical performance and quality of life, since low frequent postop-
erative deficits might be more important in regard to survival and quality of life than increasing the 
EOTR with several percentiles A subset of 3 out of 12 studies reported on statistically significant pro-
longed survival in the GTR group compared to the group that had subtotal resection. However, in 2 of 
these 3 studies, all patients were operated with iMRI, so the additional value of iMRI remains unclear 
and in the other study a non-randomized mix of iMRI and cNN cases was reported with the potential 
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of substantial bias. In all cases no inference could be made between use of iMRI and increased  
survival. 
Other limitations
Another frequently occurring limitation is that control groups may not be equivalent to study 
groups.[14,58,19] This concerns mainly tumor location and different navigation systems (historic  
control group that was operated with earlier navigation systems). Tumor location is of prominent  
importance, since the EOTR is directly related to the eloquence of the tumor location. Also the time 
points when clinical performance is measured varies between studies (before discharge or at three 
months after surgery). This makes a valid comparison of the results difficult. 
A further issue of concern is the definition of tumor volume. Defining glioblastoma as the contrast  
enhancing area on T1-weighted MRI is common practice. Although phenomena as pseudoprogres-
sion[64] and pseudo-enhancement[64] are not applicable to an early postoperative MRI within 72 
hours after surgery, it is questionable whether the volume to be resected is best defined by contrast 
enhancement. New imaging techniques may allow for other (and maybe better) methods to visualize 
glioblastoma volume, like MR perfusion or MR spectroscopy. This translates to an issue of concern 
for the future use of iMRI, as only high-field strength iMRI systems are currently able to provide such 
image modalities with acceptable quality within an acceptable time span. 
Recommendations for future research
Based on the results of this systematic review there are a few recommendations for future studies on 
iMRI-guided glioblastoma resection. First, if residual tumor volume or resection percentage is to be 
used as a primary endpoint, it is mandatory to have a clear definition of postoperative tumor volume 
and a valid method to measure this. Currently volumetry cannot serve as a valid endpoint, mainly due 
to unacceptable low interobserver agreement for postoperative tumor volume and, therefore, residual 
tumor volume. 
Second, (more) randomized comparisons between different types of image-guided surgery seem to 
be in place. Besides iMRI these include intraoperative ultrasound, intraoperative CT and 
fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA). Particularly the latter has been dem-
onstrated to enable more complete resections of contrast-enhancing tumor, leading to improved 
progression-free survival in patients with malignant glioma.[60] A relatively small phase II study could 
explore which technique brings the best GTR rate. A more fundamental question is whether 5-ALA 
guided surgery should not be implemented first, knowing that this improves EOTR for malignant 
glioma. iMRI can then be added and compared to this proven technique. Of note, the implementation 
5-ALA is considered to be more simple and less costly for this type of tumors. 
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Third, outcome data should be more detailed, not only including clinical performance (from a physi-
cian’s standpoint) but also quality of life data (from a patient’s standpoint). Such data should be 
weighed against EOTR and survival to find a balance that may be considered as optimal treatment 
for glioblastoma patients. For this patient population maximizing EOTR might be less helpful than 
maximizing quality of life. Quality Adjusted Life Years (QALYs) are an excellent outcome parameter to 
measure this, and allow for comparison between different types of treatment (both non-surgical and 
surgical). 
Fourth, more studies on cost-benefit for iMRI are welcomed. There are only a few studies dealing with 
this issue, reporting on a mixed patient population.[14,24,26] As iMRI is an expensive technique,  
economic justification is an issue of concern. 
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Based on the available literature there is currently at best level 2 evidence that iMRI-guided surgery 
is more effective than cNN-guided surgery in (significantly) increasing EOTR, enhancing quality of life 
or prolonging survival in glioblastoma patients. Higher quality studies on iMRI are necessary to  
demonstrate its added value compared to standard treatment. If EOTR is to be used as a primary 
endpoint, we need a clear definition on postoperative tumor volume and a valid method to measure 
this volume. For the future it will become more important to weigh this added value against the cost, 
for example using QALYs (Quality Adjusted Life Years) as an outcome parameter. Social and economi-
cal forces oblige us to perform better quality research in order to offer the best possible treatment to 
our patients while keeping healthcare affordable. A randomized trial with validated endpoints is  
necessary to demonstrate the actual added value of iMRI-guided surgery. 
CONCLUSION AND SUGGESTIONS
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VOLUMETRY
The role of extent of tumor resection (EOTR) in improving outcome for patients with glioblastoma is 
still under debate. In a recent review, Sanai et al. concluded that despite persistent limitations in the 
quality of data, mounting evidence suggests that more extensive surgical resection is associated with 
longer life expectancy for both low and high grade glioma.[11] Reproducibility of EOTR measure-
ments is important. Several methods have been developed for response assessment of glioma treat-
ment, like the MacDonald criteria and RECIST.[5,8,17] None of these are specific for measuring 
EOTR. To evaluate the effect of surgical treatment, volumetry may be superior to linear assessment of 
tumor volume. Three studies reported on EOTR of glioblastoma with volumetry of pre- and postopera-
tive MRI.[6,7,10] Two other studies reported on EOTR of high grade glioma removal with volumetry on 
intraoperative MRI.[9,12] None of these studies assessed intraobserver or interobserver agreement of 
this method. The purpose of this study is to analyze both intraobserver and interobserver agreement 
of manual segmentation as a method for volumetric assessment of glioblastoma resection.
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Patient Selection
This study was approved by the institutional ethics research board. Imaging data were collected from 
all patients that were operated in our hospital between April 2007 and April 2008 if they met these  
inclusion criteria: first brain tumor presentation, histologically proven glioblastoma, presence of a pre-
operative isovoxel contrast-enhanced MRI, and presence of a postoperative isovoxel contrast-
enhanced resection control MRI within 72 hours after surgery. A group of 8 patients met these  
criteria. This group consisted of 5 male and 3 female patients between 48 and 76 years of age (mean 
age 61 years). The data were prospectively analyzed using the method described later in this sec-
tion. 
Imaging
MRI scans were made with the Intera 1.5T MRI system (Release 11.1; Philips, Best, The Netherlands). 
Preoperative and postoperative tumor volumes were measured on contrast-enhanced T1-weighted 
volumescans (isovoxel 1 mm, gap thickness 0 mm). Gadopentetate dimeglumine (Magnevist; Bayer-
Schering Pharma AG, Berlin, Germany) was used as contrast agent in a dose of 0.2 ml/kg. All postop-
erative scans were performed within 72 hours after surgery. 
Expertise of the observers
The observers are a senior resident in neurosurgery (PK), a neurosurgeon (HvS), and a  
neuroradiologist (AP). All observers are acquainted with interpreting MRI for brain tumor. 
Definition of tumor volume
For preoperative and postoperative MRI, glioblastoma was defined as the contrast-enhancing mass 
with enclosed necrosis. Three observers performed manual segmentation of what they considered to 
be glioblastoma on all slices of both pre- and postoperative MRI. All observers studied all MRI scans 
twice, with a minimum time interval of two weeks. Each observer was blinded for the results of other 
observers. Measurements were performed on regular PC’s running MS Windows operating system, 
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within the Philips iSite-client of our Picture Archiving and Communication System (PACS) (Philips 
Healthcare Informatics Headquarters, Foster City, CA). Tumor volume (TV) was calculated by sum-
ming all segmented slice areas (SA, in cm2) within a series, multiplied by the slice thickness (0.1 cm):
TV (in cm3) =  sum (SA) x 0.1
Residual tumor volume percentage (RTV) was calculated by dividing postoperative tumor volume 
(PostTV) by preoperative tumor volume (PreTV), multiplied by 100%: 
RTV (in %) = PostTV / PreTV x 100
Statistical analysis
Intraclass correlation coefficients (ICCs) were calculated using SPSS 16.0.1 for Mac (SPSS Inc, Chi-
cago, IL) by using Reliability Analysis with a one-way random model and 95% confidence intervals 
(CI). This was done for intraobserver and interobserver agreement of PreTV, PostTV and RTV. 
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Measurements
Data from volumetric analysis are displayed in Table 3.1. The rows show the three categories (PreTV, 
PostTV, RTV) per patient. The columns show the results for each observer. Volumes from first and  
second measurements are separated by a forward slash. 
Time investment for segmentation
An average manual segmentation of PreTV or PostTV included approximately 40 slices nd took circa 
30 minutes each. The required amount of time to analyze one patient once was at least 60 minutes.
Intraobserver agreement
ICCs with CI are displayed in Table 3.2. Intraobserver agreement was high for PreTV (ICC = 0.99), for 
PostTV and for RTV (ICC = 0.89 – 0.94). The low ICC for PostTV measured by observer 3 (ICC = 
0.73) can be explained by patient 8, in which second PostTV measurements were twice the value of 
the first measurements. If this patient would be discarded, PostTV ICC for observer 3 is 0.90. 
Interobserver agreement
Interobserver agreement was high for PreTV (ICC = 0.97), but low for PostTV (ICC = 0.54) and RTV 
(ICC = 0.52). ICCs and CI for interobserver agreement are also displayed in Table 3.2.
Graphs
Figures 3.1, 3.2 and 3.3 show the measurements for PreTV, PostTV and RTV respectively. High  
intraobserver agreement means that all identical symbols (square, triangle or circle) are located 
closely together. High interobserver agreement  means that all symbols are located closely together. 
Figure 3.1 clearly shows a high intraobserver and interobserver agreement for PreTV, that decreases 
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for PostTV (Figure 3.2) and therefore for RTV (Figure 3.3). Figure 3.4 shows that interobserver agree-
ments decreases if PostTV exceeds 20cm3.
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Table 3.1: Data from volumetric analysis of eight patients with three observers
Observer 1 Observer 2 Observer 3
Patient 1
PreTV
PostTV
RTV
Patient 2
PreTV
PostTV
RTV
Patient 3
PreTV
PostTV
RTV
Patient 4
PreTV
PostTV
RTV
Patient 5
PreTV
PostTV
RTV
Patient 6
PreTV
PostTV
RTV
Patient 7
PreTV
PostTV
RTV
47.17 / 47.43
15.43 / 11.85
32.70 / 24.99
55.12 / 54.76
28.85 / 25.29
52.35 / 46.19
52.54 / 52.95
22.14 / 20.24
42.13 / 38.22
42.46 / 40.77
6.27 / 6.46
14.77 / 15.84
47.04 / 49.31
32.52 / 28.22
69.13 / 57.23
46.07 / 46.45
31.76 / 25.76
68.94 / 55.46
64.62 / 66.05
6.08 / 6.75
9.40 / 10.21
77.26 / 79.28
13.38 / 13.16
17.32 / 16.59
77.06 / 72.98
9.80 / 12.14
12.72 / 16.63
94.09 / 91.32
17.08 / 15.18
18.15 / 16.62
120.37 / 117.03
43.29 / 31.68
35.96 / 27.07
124.05 / 109.18
23.50 / 31.26
18.94 / 28.63
24.18 / 23.38
3.82 / 2.94
15.79 / 12.59
28.92 / 30.39
10.15 / 11.62
35.09 / 38.22
27.07 / 27.98
5.07 / 7.06
18.73 / 25.23
80.06 / 79.99
7.36 / 6.21
9.19 / 7.76
88.09 / 87.36
10.23 / 13.25
11.61 / 15.17
84.20 / 86.70
12.47 / 12.93
14.81 / 14.91
89.08 / 89.44
3.34 / 4.05
3.75 / 4.52
99.74 / 96.11
15.19 / 16.83
15.22 / 17.51
96.00 / 99.32
15.31 / 16.37
15.95 / 16.48
Table 3.1 (continued): Data from volumetric analysis of eight patients with three observers
Observer 1 Observer 2 Observer 3
Patient 8
PreTV
PostTV
RTV
120.93 / 120.17
18.98 / 24.68
15.70 / 20.54
133.91 / 132.03
49.27 / 48.82
36.79 / 36.98
134.54 / 134.83
22.73 / 40.55
16.89 / 30.07
Explanation: tumor volumes are expressed in cm3 and results from first and second measurement 
are divided by a forward slash. PreTV = preoperative tumor volume; PostTV = postoperatve tumor 
volume; RTV = residual tumor volume percentage.
Figure 3.1: PreTV measurements for each observer.
45
Figure 3.3: RTV measurements for each observer 
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Figure 3.2: PostTV measurements for each observer 
Figure 3.4: Comparison of PostTV in cm3 in first (PostTV01) and second (PostTV02) measurements.
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Figure 3.5: Postoperative illustration of case with low interobserver and even low intraobserver 
agreement without (5a) and with (5b) observers’ segmentations.
This study shows that volumetric assessment of glioblastoma resection provides consistent results for 
an individual observer, but variable results between different observers. This implies that absolute 
RTV values or RTV percentages relating EOTR to survival may be unreliable. 
Response assessment
The MacDonald criteria are widely used for response assessment in glioma.[8] The approach of  
bidirectional measurements of the contrast-enhancing tumor area has its limitations.[1,16,4]  For surgi-
cal response assessment, the often irregular shape of high grade gliomas is the most important one. 
Besides surgical manipulation, contrast enhancement can be influenced by a variety of circum-
stances: corticosteroids, radionecrosis, pseudoprogression (after temozolomide) and pseudo-
response (after antiangiogenesis agents).[1] These are important for postoperative follow-up. For  
presurgical tumor size assessment, unidirectional measurements could form a validated method to 
assess tumor volume.[17,3,13,18] But this approach works only for an approximately spheric  
tumor,[5] and is therefore not useful postoperatively.
Volumetry may be a better method for surgical response assessment, if measurements are based on 
the contrast-enhancing area. Sorensen showed an improved intraobserver and interobserver agree-
ment for perimeter methods compared to diameter methods for tumor volume calculation.[15] No 
postoperative data were available in that study. Duong et al. described a volumetric approach to  
assess EOTR and used phantom scans to analyze the accuracy of the software and its users,[2]  
However, their protocol required digitizing CT film images with a slide scanner and recording them on 
a personal computer hard disk. Shi et al. improved this technique to enable direct input of MRI data, 
transferred by optical disks.[14] Both studies assessed intraobserver variability, which was estimated 
to be 1.7% and 1.8% respectively. These studies are only partially comparable to ours. None of these 
studies used volumescans, no ICCs were calculated and interobserver agreement was not men-
tioned. 
Observer agreement
We calculated ICC for intraobserver and interobserver agreement of PreTV, PostTV and RTV on  
volumescans. We defined tumor volume as the contrast-enhancing mass with enclosed central necro-
DISCUSSION
48
sis: this is consistent with other authors.[6,7,12] This definition does not correct for hyperintensities 
that are already visible on native T1-weighted MRI. Nimsky et al. used coregistration of all imaging 
data sets (e.g. T1-weighted, T2-weighted, fluid attenuated inversion recovery) for more accurate  
confirmation of the tumor contour.[9] This approach may result in a more accurate estimation of  
glioblastoma resection, but was not done in other studies and is not available on many computer  
systems. Besides, it is very labor-intensive. Our analysis took about 60 minutes per patient, which is 
likely to increase when using additional datasets for coregistration. Therefore this method is not  
usable in daily practice if not automated in the future. 
The observers in our study compared their results to explain the low interobserver agreement for 
PostTV. Different interpretation of what to consider as postoperative tumor in an individual patient 
proved to be the main explanation for the low interobserver agreement. Areas that may be interpreted 
as either necrosis (representing residual tumor) or resection cavity formed the main difficulty. This 
was more prominent when PostTV exceeded 20cm3 (Figure 3.4). Increased PostTV is associated with 
an increased number of slices: therefore the number of interpretation differences does increase as 
well. A typical case with low interobserver and even low intraobserver agreement (patient 4) is repre-
sented in Figure 3.5. 
Strengths and limitations
The main strength of this study is that, to our opinion, it is the first study to address both intraobserver 
and interobserver agreement for glioblastoma volumetry. Measurements are performed on volume-
scans, which provide the best spatial resolution in all directions. The study involved observers from 
the field of neurosurgery and neuroradiology. The time interval between the first and second measure-
ments prevented the observers from remembering their segmentation decisions of the previous time. 
The main limitations of our study are the poor definition of postoperative tumor volume and the low 
number of patients. Defining glioblastoma as “the contrast-enhancing mass with enclosed necrosis” 
resulted in different interpretations when measured on contrast-enhanced T1-weighted MRI only. 
Despite the limited number of patients, our results suggest that using manual segmentation to  
measure (especially large) PostTV is associated with low interobserver agreement. In these cases 
EOTR has to be assessed with great caution. 
Suggestions
At least two aspects need to be addressed to establish a validated method for volumetric assess-
ment of glioblastoma resection that is useful in daily practice. 
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First, “postoperative tumor” needs to be defined more clearly. Issues that need to be clarified are how 
to deal with enclosed hypointensities on postoperative MRI and hyperintensities on native T1-
weighted MRI. Regarding hypointensities suspected to be necrosis, we consider “central necrosis” 
not to be a satisfactory description. On postoperative T1-weighted MRI discrimination between the 
resection cavity and residual necrosis can be difficult in a single plane (Figure 4). Only cyst-like parts 
that are surrounded by contrast-enhancing tissue should be considered as residual tumor with  
central necrosis. Otherwise we should consider these cyst-like parts to belong to the resection cavity. 
For that reason we prefer “enclosed necrosis” over “central necrosis”,  Regarding hyperintensities on 
native T1-weigthed MRI, they can relate to blood products in the resection cavity instead of residual 
tumor. When manually correcting for these hyperintensities, interobserver variability and time invest-
ment are issues of concern. 
Second, computer-aided approaches should be implemented to facilitate segmentation of postopera-
tive tumor. Software algorithms can be used to determine if cyst-like parts represent residual tumor or 
belong to a resection cavity: in the first case, they will be surrounded by contrast-enhancing tissue in 
all directions. Subtracting hyperintensities on native T1-weighted MRI from hyperintensities on 
contrast-enhanced T1-weighted MRI should reduce different interpretations of postoperative glioblas-
toma volume. Afterwards the software can quantify the remaining volume of interest. 
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Volumetric assessment of glioblastoma resection seems to offer high intraobserver agreement, but 
low interobserver agreement. The results of this study suggest that using absolute residual tumor  
volume to relate EOTR with survival may be unreliable, especially for larger tumor volumes. More  
research is needed before this method can be used as a valid endpoint for clinical studies. 
Computer-assisted tumor volume calculation may increase interobserver agreement in the future. 
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BORDERZONE 
SAMPLING STUDY
Glioblastoma is a highly malignant brain tumor that often shows extensive infiltrative growth in the  
surrounding brain parenchyma. Standard treatment consists of surgery, radiotherapy and chemo-
therapy, leading to a median survival of 14.6 months.[30,29] Although the role of surgery is still under 
debate, mounting evidence suggests that increased extent of tumor resection (EOTR) is associated 
with prolonged survival.[24] Intraoperative MRI (iMRI) is a technique that can help to increase EOTR, 
comparable to the use of 5-aminolaevulinic acid (5-ALA).[27]
The added value of iMRI in increasing EOTR for glioblastoma is based on visualizing remaining con-
trast enhancement on T1-weighted scans at the border of the resection cavity.  This contrast enhance-
ment is supposed to indicate residual tumor, which can be resected in the same procedure. In a few 
studies the additionally resected tissue was sent separately for histological analysis, leading to  
varying reports on tumor presence.[26,21,17] However, due to the infiltrative nature of a glioblastoma, 
tumor cells are often present outside the contrast enhancing area.[5,1] If contrast enhancement on 
T1-weighted iMRI is to be used as a marker for high grade glioma, then contrast enhancing tissue 
should exhibit more high grade tumor characteristics than non (contrast) enhancing tissue. Serial 
stereotactic biopsies have been performed on preoperative CT and MRI, demonstrating tumor cells 
outside the contrast enhancing area.[9] To our knowledge, such studies have not been performed 
systematically on iMRI, in which contrast agent is administered after tumor resection (i.e. after possi-
ble iatrogenic damage to the blood brain barrier). Therefore, histologic results correlated to preopera-
tive imaging might not correlate to iMRI. 
This is the first study that systematically compares contrast enhancement on iMRI with  
histopathological characteristics in glioblastoma. The study objective is to determine to what extent 
contrast enhancement on T1-weighted iMRI can be used as a marker for presence of (high grade) 
glioma, and therefore as a valid indicator to assess EOTR. 
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The study protocol is registered at ClinicalTrials.gov under number NCT00780819 and has been  
approved by the institutional ethics research board. 
Patient selection
For this prospective cohort study we recruited 10 patients with a supratentorial brain tumor suspect 
for a glioblastoma. We determined the number of patients to be included based on consensus in the 
study committee. Inclusion criteria were: indication for tumor resection, minimum age of 18 years, 
WHO Performance Scale 2 or better, ASA class 3 or better, understanding of the Dutch language, 
and informed consent. Exclusion criteria were: recurrent tumor, multiple tumor locations, prior radio-
therapy on the skull, and prior chemotherapy. 
Study endpoints
Primary endpoint of this study was the correlation between contrast enhancement at the border of the 
resection cavity on T1-weighted iMRI and presence of high grade tumor according to the WHO 
classification.[16] Secondary endpoints of this study were: correlation between contrast enhance-
ment at the border of the resection cavity on T1-weighted MRI and other histopathologial tissue char-
acteristics, postoperative clinical condition, and survival. 
Surgical procedure
All study participants were operated by a neurosurgeon (OS, MtLP or HvS) sufficiently experienced 
with the 0.15 Tesla iMRI system used in our hospital (PoleStar N20 with Stealth Station extension;  
Medtronic Navigation, Louisville, CO). After patient installation in the headclamp, a contrast  
enhanced preoperative (high-field strength) MRI was loaded for surgical planning and initial neuro-
navigation. Before incision a non enhanced iMRI scan was made as a baseline scan that intraopera-
tively acquired scans could be compared with. 
During tumor resection, resected tissue was sent for standard histopathological analysis. As soon as 
the neurosurgeon considered the intended tumor resection to be complete, T1-weighted iMRI scans 
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were acquired using the so-called “T1 7min 4mm”-protocol in axial orientation: first a non enhanced 
scan, then a contrast enhanced scan using gadopentetate dimeglumine (Magnevist; Bayer-Schering 
Pharma AG, Berlin, Germany). Contrast dose was 0.4 ml/kg (0.2 mmol/kg) – a so-called “double-
dose” - provided no renal failure was present. The contrast enhanced scan was made immediately 
after intravenous contrast administration. 
After scanning neuronavigation was continued on the contrast enhanced iMRI scan, which was  
imported in the Stealth Station neuronavigation system. In all directions where gross total resection 
was intended, neuronavigation-guided biopsies were taken at the border of the resection cavity. A 
screen capture from the neuronavigation system was saved for each biopsy to relate contrast en-
hancement with histopathology. Each biopsy was sent separately for histopathological analysis,  
labeled with a number corresponding to the screen capture. After taking the biopsies, surgery was 
continued to resect any contrast enhancement in a direction where gross total resection was  
intended. Scanning was repeated if this goal was considered to be achieved, and additional biopsies 
were taken if safely possible. Contrast administration was only repeated if the previous iMRI scan was 
performed more than 2 hours ago, in a dose of 0.2 mml/kg (0.1 mmol/kg) – a “single-dose” - provided 
no renal failure was present. 
Perioperative procedure
Preoperative and postoperative MRI scans were made with the Intera 1.5 Tesla MRI system (Release 
11.1; Philips, Best, The Netherlands). Preoperative neuronavigation scans were contrast-enhanced 
T1-weighted volume scans (isovoxel 1 mm, gap thickness 0 mm). Postoperative multiple sequences 
were acquired in a standardized fashion, including contrast enhanced T1-weighted sequences.  
Gadopentetate dimeglumine was used as a contrast agent in a dose of 0.2 ml/kg (0.1 mmol/kg) pro-
vided no renal failure was present. 
All preoperative and postoperative scans were performed within 72 hours before and after surgery 
respectively. 
WHO Performance Scale was measured the day before surgery, and one week after surgery. 
Determination of contrast enhancement
The screen captures from the biopsy locations were independently reviewed by a neurosurgeon and 
a senior resident in neurosurgery (HvS and PK). Both have ample experience in interpreting PoleStar 
images. Contrast enhancement was scored according to a four-tier classification described by Ekinci 
et al, displayed in Table 4.1: none, thin linear, thick linear, and (suspected) residual tumor.[4] Screen 
captures that were scored differently by the reviewers were reviewed together to obtain consensus. 
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Determination of histopathological characteristics
The biopsy tissue samples were independently reviewed by two experienced neuropathologists (PW 
and ML), blinded for corresponding contrast enhancement. Histopathological characteristics were 
scored for 10 parameters (most of these in a semiquantitative fashion): amount of tissue, quality of  
tissue, preexistent tissue, increased cellularity, tumor presence, mitoses, vascular changes, necrosis, 
inflammation, and WHO grade in the sample. To each individual biopsy specimen in which tumor was 
present a WHO grade was assigned according to the WHO 2007 classification of tumors of the  
central nervous system[15]: grade II = no mitotic activity, no necrosis and no florid microvascular  
proliferation found; grade III = mitotic activity present, but absence of necrosis and florid microvascu-
lar proliferation; grade IV: presence of necrosis and/or florid microvascular proliferation. The values 
for each parameter are displayed in Table 4.2. 
The so-called “Tier 1 items” to be reported according to the “Biospecimen reporting for improved 
study quality” (BRISQ) recommendations are displayed in Table 4.3.[18] Tissue samples that were 
scored different by the neuropathologists were reviewed together to obtain consensus. 
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Table 4.1: Ekinci classification for scoring contrast enhancement
Description Definition
None No visible contrast enhancement
Thin linear Resembles normal dural enhancement (< 5 mm)
Thick linear Thicker than typical dural enhancement (5 – 10 mm)
Suspected residual tumor > 10 mm in any imaging plane
Table 4.2: Classification for histopathological characteristics
Parameter Values
Preexistent tissue white matter, gray matter, combination, indeterminate
WHO grade no WHO grade: non-neoplastic (normal or reactive changes); WHO 
grade II: low grade diffuse astrocytoma; WHO grade III: anaplastic 
astrocytoma; WHO grade IV: glioblastoma
Vascular changes no apparent, vasodilatation, hypertrophic endothelium, florid 
microvascular proliferation
Necrosis absent, indeterminate, focal, local, extensive
Mitoses no, sparse, moderate, frequent
Increased cellularity no apparent, limited, moderate, marked
Table 4.3: BRISQ Tier 1 items
Data element Value
Biospecimen type Perifocal brain tumor parenchyma
Anatomic site Cerebrum
Disease status of patients WHO Performance Scale ≤ 2
Clinical characteristics of patients Neurological deficit dependent on tumor location
Vital state of patients Alive
Clinical diagnosis of patients Supratentorial intra-axial brain tumor, suspect for high grade 
glioma
Pathology diagnosis Glioblastoma 
Collection mechanism Tumor forceps
Type of stabilization Saline 0.9% solution
Type of long-term preservation Formalin-fixed, paraffin embedded
Constitution of preservative 10% neutral-buffered formalin
Storage temperature Room temperature
Storage duration 6 – 18 months
Relocation temperature Room temperature (after embedding in paraffin)
Composition assessment & 
selection
Scored as “adequate” regarding “amount of tissue” and “quality 
of tissue”
Statistics
Interobserver agreement for contrast enhancement, WHO classification and histopathological  
parameters were expressed as kappa-squared values, calculated with an in-house made application. 
Correlation between contrast enhancement and histopathological parameters was expressed as Ken-
dall’s tau with a one-tailed significance, calculated in PASW Statistics version 18.0.3 for Mac (IBM Cor-
poration, Armonk, NY). Further analysis consisted of creating crosstables to calculate sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio 
(LR+) and negative likelihood ratio (LR-) for contrast enhancement in relation to WHO grade. Two  
definitions were used for presence of contrast enhancement: “thick linear + tumor-like” versus “thin 
linear + thick linear + tumor-like”. Also, two definitions were used for presence of tumor: “grade III + 
grade IV” versus “grade II + grade III + grade IV”.  Calculations were performed with Microsoft Excel 
for Mac version 2011 (Microsoft, Redmond, WA), as well as the graphical representation of the  
interobserver agreement. 
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Patient characteristics
Table 4.4 shows relevant characteristics of the 10 participants included in this study, including  
information on tumor location, and preoperative and postoperative WHO Performance Status (WPS). 
Patients were recruited between October 2008 and July 2009, and follow-up lasted until all patients 
died. Age varied between 46 and 71 years, with a mean of 59.7 ± 9.0 years. Six patients were male 
and four patients were female. The main tumor mass was located in the left versus right cerebral 
hemisphere in six and four patients, respectively, and the tumor was most frequently located in the 
frontal lobe (n=4), followed by the temporal lobe (n=3), parietal lobe (n=2) and occipital lobe (n=1). 
All patients but one were administered a double-dose of contrast agent, the remaining patient  
received a single-dose because  of pre-existing renal dysfunction, which was however not a contra-
indication for gadolinium-based contrast agent. Standard histopathological examination of the  
RESULTS
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Table 4.4: Study demographics
Code Sex, Age (y) Tumor 
location
WPS pre/
post
Contrast 
dose *
2nd scan 
delay
NoS NoATS
BZS01 M, 51 L frontal 0 / 0 double N/A 5 5
BZS02 M, 60 R frontal 0 / 1 double 115 min 5 + 1 4 + 1
BZS03 M, 62 L temporal 0 / 1 single N/A 2 2
BZS04 F, 69 L frontal 1 / 1 double 90 min 5 + 3 5 + 3
BZS05 M, 46 L temporal 1 / 1 double N/A 3 2
BZS06 F, 61 L parietal 1 / 1 double N/A 5 4
BZS07 F, 47 R temporal 2 / 2 double N/A 3 3
BZS08 M, 71 R occipital 1 / 1 double N/A 4 3
BZS09 F, 69 L frontal 1 / 1 double N/A 4 3
BZS10 M, 61 R parietal 0 / 0 double N/A 2 1
Abbreviations: F = female, L = left, M = male, min = minutes, N/A = not applicable, NoATS = 
Number of Adequate Tumor Samples, NoS = Number of Samples, post = postoperative, pre = 
preoperative, R = right, WPS = WHO Performance Status, y = years.
* A single dose of contrast is 0.1 mmol/kg, a double dose is 0.2 mmol/kg.
resected tumor revealed glioblastoma as the clinical diagnosis for all patients. The total number of 
study biopsy samples of all patients was 42. The number of biopsy samples per patient varied  
between 2 and 8, with a mean of 4.2 ± 1.9 samples. In two patients biopsy samples were taken in two 
different phases during surgery. In those cases the delay between the first dose of contrast admini-
stration and the second iMR scan was 115 and 90 minutes, respectively, and according to our proto-
col no new dose of contrast agent was administered before the second iMR scan. Preoperative WPS 
varied between 0 and 2, with a mean of 0.7 ± 0.7. Postoperative WPS varied between 0 and 2, with a 
mean of 0.9 ± 0.6.  Two patients (BZS02 and BZS03) suffered from transient neurological deficit post-
operatively, one due to a supplementory motor area (SMA) syndrome and another due to postopera-
tive haemorrhage. Both patients recovered within a few days from WPS 3-4 to WPS 1. All patients  
received the standard t reatment consist ing of radiotherapy and chemotherapy 
postoperatively.[30,29] Postoperative survival varied between 40 and 721 days, with a mean of 350 ± 
215 days (median 372 days). Of note, the patient with the shortest survival (BZS05) opted for  
euthanasia. Postoperative survival is displayed as a Kaplan-Meier curve in Figure 4.1. 
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Figure 4.1: Kaplan-Meier curve displaying postoperative survival
Interobserver agreement
A total of 42 samples were available for further analysis, 39 of these were scored as “adequate” both 
on “amount of tissue” and “quality of tissue”. Table 4.5 shows the results for both observers for con-
trast enhancement and tissue characteristics for these 39 samples. 
Table 4.5b: Interobserver comparison for “WHO grade”
Normal / NT RC Grade II Grade III Grade IV
Normal / NT
RC
Grade II
Grade III
Grade IV
6 1 0 0 0
1 0 0 0 0
0 1 4 0 0
0 0 3 0 4
0 0 2 2 12
Abbreviations: NT = No Tumor, RC = Reactive Changes
Table 4.5c: Interobserver comparison for “preexistent tissue”
Grey + white White Grey Indeterminate
Grey + white
White
Grey
Indeterminate
9 2 1 1
3 4 0 2
5 1 0 1
0 1 0 12
Table 4.5d: Interobserver comparison for “increased 
cellularity”
Extreme Marked Moderate Limited No apparent
Extreme
Marked
0 2 0 1 0
0 6 9 1 0
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Table 4.5a: Interobserver comparison for “contrast enhancement”
None Thin linear Thick linear Residual tumor
None
Thin linear
Thick linear
Residual tumor
20 1 0 0
2 5 2 4
0 1 2 3
0 0 0 2
Table 4.5e: Interobserver comparison for “vascular changes”
No apparent Vasodilatation + HT + Florid MVP
No apparent
Vasodilatation
+ HT
+ Florid MVP
10 1 0 0
7 2 1 0
2 1 3 4
0 0 1 7
Abbreviations: HT = hypertrophic endothelium, MVP = microvascular proliferation
Table 4.5f: Interobserver comparison for “necrosis”
Extensive Local Focal Indeterminate Absent
Extensive
Local
Focal
Indeterminate
Absent
4 0 0 0 1
2 1 0 0 0
0 1 0 0 1
0 0 0 2 3
0 0 3 1 23
Table 4.5g: Interobserver comparison for “mitoses”
Frequent Moderate Sparse No
Frequent
Moderate
Sparse
No
1 2 3 0
1 3 0 0
0 0 4 4
0 0 4 20
Interobserver agreement is calculated for each parameter and expressed as kappa-squared with 
95% confidence intervals in Figure 4.2. For all biopsies, tumor parameters that were scored differently 
by both observers were scored again, now by both observers simultaneously. This consensus-based 
final value was chosen for further analysis. 
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Figure 4.2: Interobserver agreement for each tumor parameter expressed in kappa-squared 
(CI = confidence interval)
Correlation between contrast enhancement and tumor
Of the 39 adequate biopsy samples, 3 had an uncertain diagnosis regarding WHO grade. Correla-
tions between contrast enhancement and tumor were calculated using the remaining 36 samples and 
displayed in Table 4.6. Four tumor parameters demonstrated a significant correlation with contrast  
enhancement: WHO grade, vascular changes, necrosis and increased cellularity. In particular the 
first three demonstrated highly significant but only moderately strong correlation, with Kendall’s tau 
values around 0.50. The parameter “tumor presence” was found to have no additional value over the 
information obtained by combining grade II, III and IV lesions in the parameter “WHO grade”. Further-
more, substantial interobserver variation for the parameter “inflammation” prevented meaningful  
analysis of this parameter. Therefore, the parameters “tumor presence” and “inflammation” are not  
further incorporated in the tables and results. 
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Subgroup analysis
To gain more insight in the type of correlation, crosstables are created to relate the values for contrast 
enhancement with the respective values for each tumor parameter. The results are presented in Table 
4.7, and used to calculate sensitivity, specificity, PPV, NPV, LR+ and LR-. 
Table 4.7a: Crosstable for “contrast enhancement” with “WHO grade”
Normal / NT Grade II Grade III Grade IV
No enhancement
Thin linear
Thick linear
Suspected tumor
6 4 3 4
2 1 2 3
0 0 1 5
0 0 0 5
Abbreviations: NT = No Tumor
Table 4.7b: Crosstable for “contrast enhancement” with “increased cellularity”
No apparent Limited Moderate Marked
No 
enhancement
Thin linear
Thick linear
Suspected 
tumor
5 4 6 4
2 1 3 2
1 0 3 3
0 0 3 2
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Table 4.6: Correlation coefficients for “contrast enhancement” related to other tumor parameters
Tumor parameter Kendall’s tau Significance * NoS
WHO grade
Vascular changes
Necrosis
Mitoses
Increased cellularity
0.50 <0.01 36
0.53 <0.01 38
0.49 <0.01 39
0.09 0.27 39
0.26 0.03 39
Abbreviation: NoS = Number of Samples (available for statistical analysis per tumor parameter)
* The 1-tailed significance is expressed in a p-value.
Table 4.7c: Crosstable for “contrast enhancement” with “vascular changes”
No apparent Vasodilatation + HT + Florid MVP
No enhancement
Thin linear
Thick linear
Suspected tumor
11 2 4 2
2 3 2 1
0 2 1 3
0 0 0 5
Abbreviations: HT = hypertrophic endothelium, MVP = microvascular proliferation
Table 4.7d: Crosstable for “contrast enhancement” with “necrosis”
Absent Indeterminate Focal Local Extensive
No enhancement
Thin linear
Thick linear
Suspected tumor
17 0 2 0 0
4 1 1 0 2
1 1 0 2 3
2 0 2 0 1
Table 4.8 shows these values for the correlation between “contrast enhancement” and “WHO grade” 
using two definitions for each parameter (see also Materials and Methods). If “contrast enhancement” 
is defined as “thick linear” plus “tumor-like” then the PPV is 1 and the LR+ goes to infinity, regardless 
of tumor definition (only high grade components versus low grade components as well). Sensitivity is 
0.48 if only high grade components are included, and 0.39 if low grade components are included as 
well. If “contrast enhancement” is defined including “thin linear” enhancement, then specificity falls to 
circa 0.75 and sensitivity rises to 0.70 (for only high grade components) or 0.61 (including low grade 
components). 
Figure 4.3 contains a web diagram illustrating the sensitivity and specificity of contrast enhancement 
(using two definitions) for all significantly correlated tumor parameters. 
Sensitivity, NPV and LR- all vary around 0.50. This means that half of the histologically confirmed  
“tumor samples” show contrast enhancement, and half do not. Also, half of the contrast enhancing 
samples are classified as “tumor”, and half are not. 
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Table 4.8: Subgroup analysis correlating “contrast enhancement” and “WHO grade” using two 
definitions per parameter
Contrast definition
Tumor definition *
thick linear + 
tumor-like
thick linear + 
tumor-like
thin linear + thick 
linear + tumor-like
thin linear + thick 
linear + tumor-like
III + IV II + III + IV III + IV II + III + IV
Sensitivity
Specificity
PPV
NPV
LR+
LR-
0.48 0.39 0.70 0.61
1.00 1.00 0.77 0.75
1.00 1.00 0.84 0.89
0.52 0.32 0.59 0.35
∞ ∞ 3.01 2.43
0.52 0.61 0.40 0.52
Abbreviations: LR- = Negative Likelihood Ratio, LR+ = Positive Likelihood Ratio, NPV = Negative 
Predictive Value, PPV = Positive Predictive Value, thick linear = Thick Linear enhancement, thin 
linear = Thin Linear enhancement, tumor-like = Suspected residual tumor enhancement
* Tumor definition is expressed in “WHO grade” as explained in the Methods section
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Figure 4.3: Web diagram demonstrating sensitivity and specificity of contrast enhancement  
(using two definitions) for all significantly correlated tumor parameters. 
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The goal of a “gross total resection”, or “complete resection of enhancing tumor” (CRET) [31] of a  
glioblastoma is to resect the contrast enhancing part as visualized on T1-weighted MRI. However,  
tumor cells are known to be present outside this contrast enhancing area,[5,1] and recent studies 
comparing contrast enhancement on T1-weighted MRI with diffusion weighted MRI and Positron  
Emission Tomography have demonstrated a considerable non-overlap between tumor delineation  
using these different techniques.[7,22] Our study compares contrast enhancement at the border of 
the resection cavity with histopathological tumor characteristics to determine to what extent contrast 
enhancement correlates with tumor. 
The classification we used for contrast enhancement is derived from Ekinci et al.[4] They describe 
that thin linear “dural like” enhancement leads to tumor regrowth in only 1 out of 16 cases, whereas 
thick linear enhancement leads to tumor regrowth in all cases, in particular when nodular (tumor-like) 
components are present. The study by Ekinci studied postoperative 1.5 Tesla MRI using 0.1-0.2 
mmol/kg gadolinium-DTPA. Intraoperative contrast enhancement may differ due to iatrogenic manipu-
lation and direct damage to the blood-brain barrier. Therefore we used two definitions for “contrast en-
hancement” in our study, both with and without thin linear enhancement. 
Four histological parameters are significantly correlated with contrast enhancement at the border of 
the resection cavity: WHO grade, vascular changes, necrosis and increased cellularity. Of note, these 
histological features are interrelated. For instance, diffusely increased cellularity in a brain biopsy 
sample is an important indicator for the presence of a diffuse glioma, and the presence of necrosis 
and/or florid microvascular proliferation are the histological hallmarks of high malignancy grade in a 
diffuse glioma. Furthermore, the correlation itself is relatively weak, with Kendall’s tau values of 0.49 – 
0.53 for WHO grade, vascular changes and necrosis, and a value of 0.26 for increased cellularity. As 
the Kendall’s tau is a non-parametric test that describes correlation but provides no detailed informa-
tion on the kind of correlation, we calculated sensitivity and specificity for the relation between  
contrast enhancement and tumor presence, using two definitions for each. Our results are consistent 
with Ekinci et al for thick linear + tumor-like enhancement: specificity is 1, regardless whether tumor 
definition includes what we defined as “WHO grade II”. Importantly, all patients in our study had a  
histologically proven glioblastoma. With the histological designation WHO grade II to biopsy samples 
of these patients we refer to samples in which the tumor lacked histological features of high grade  
malignancy in that particular (small) specimen. Of note, glioblastomas often show areas (e.g. in the 
diffuse infiltrative, peripheral parts) in which such histological features of high grade malignancy are 
lacking, but this does not necessarily mean that the glioblastoma originated from a less malignant pre-
DISCUSSION
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cursor lesion. Likewise, PPV and LR+ are maximal for thick linear + tumor-like enhancement regard-
less of tumor definition. Sensitivity is rather low: 0.48 when including only high grade tumor compo-
nents, and 0.39 when including grade II components as well. Comparable conclusions can be drawn 
for NPV and LR-. If we expand our definition of contrast enhancement to include thin linear enhancing 
tissue, specificity falls to circa 0.75 regardless of tumor definition, PPV varies around 0.84 – 0.89 and 
LR+ varies around 2.4 – 3.0. Sensitivity rises to 0.70 for only high grade components, and 0.61 if 
grade II components are included. NPV and LR- also improve slightly. 
Translating these numbers into practical conclusions, one can say that presence of evident contrast 
enhancement (thick linear + tumor-like) always refers to presence of tumor, regardless of whether  
histologically less malignant components are included. This is an interesting finding because “iatro-
genic damage” to the blood-brain barrier is thought to cause false-positive intraoperative contrast  
enhancement. Our results demonstrate that this is not the case for thick linear enhancement, but it 
might be an explanation for the lower specificity when thin linear enhancement is included. Note that 
we refrained from contrast administration before incision to prevent residual contrast enhancement 
after tumor resection, which possibly can cause contrast enhancement in non-tumorous tissue.[6]
Absence of tumor is always correlated with absence of thick linear enhancement and tumor-like  
enhancement. Unfortunately, our study shows that absence of contrast enhancement is not useful for 
predicting absence of tumor. In our study 41 – 68% of the biopsy samples showed tumor despite  
absence of contrast enhancement, depending on definition of enhancement (thin linear + thick linear 
+ tumor-like versus thick linear + tumor-like). 
Strengths and limitations
To the best of our knowledge this is the first report with a prospective systematic comparison of  
intraoperative contrast enhancement and histopathological tumor characteristics, with comparison of 
biopsies from contrast enhancing and non enhancing tissue as a particular added value. This is in 
contrast with previously published work.[17,21,26] Another strength is that both neuropathologists, 
evaluating the histological parameters in the biopsies, were blinded for the pattern of contrast en-
hancement. 
As far as we know, no validated scoring systems exist for contrast enhancement or for assessment of 
the histopathological characteristics of glial tumors as assessed in the present study. The scale we 
used for grading contrast enhancement has been published in an evaluation of tumor regrowth on 
postoperative MRI, and the scale we used for grading histopathological characteristics has been  
developed by two experienced neuropathologists (PW, ML). To increase reliability we assessed  
interobserver agreement for all measurements, and found this to be satisfactory except for the  
70
parameter “inflammatory changes”. Consensus-based outcomes were used for further analysis, 
thereby decreasing subjectivity and variation in measurements. 
The sample number of 10 patients may be relatively low, but the number of biopsies that was  
adequate for further analysis (n=39) was satisfactory. The number of biopsy samples per patient  
varied because (as also described in the inclusion criteria) the neurosurgeon only took biopsies in 
those directions where it was considered to be safely possible. 
Magnetic field strength is related to spatial resolution of the MR images and capacity of obtaining 
other imaging modalities (e.g. diffusion weighted imaging, MR spectroscopy). A limitation of this 
study is that our results can not automatically be transferred to high-field strength iMRI. However, we 
do not expect that using a high-field strength iMRI would result in a substantially different outcome as 
this would only increase spatial resolution. Of course, the use of additional imaging modalities could 
be of added value.
We used gadopentetate dimeglumine for this study, and gadolinium-based contrast agents are com-
monly used for (intraoperative ) MRI. An interesting alternative for neurosurgeons might be the use of 
so-called “ultrasmall particles of iron oxide” (USPIO) based agents, which have been tested on iMRI 
as well.[19,20,8] These might be less susceptible for iatrogenic damage of the blood-brain barrier, 
and could offer better correlations between thin linear contrast enhancement and tumor. Of note, in 
case of thick linear and tumor-like enhancement we found no indications for imaging artefacts (in  
particular false-positive contrast enhancement) related to damage of the blood-brain barrier. Specific-
ity for high grade tumor in this pattern of contrast enhancement equals 1.
Our study is limited to assessment of remaining tumor using iMRI. A recent study investigated the use 
of 5-ALA as a marker for representative stereotactic biopsy samples in several types of tumor, and 
found better values compared to our study for specificity (1.00) and sensitivity (0.69) in case of 
strong 5-ALA fluorescence [33]. Another study used 5-ALA to differentiate between necrosis,  
(fluorescent) “tumor cells” and (non-fluorescent) “margin cells”. They found that margin cells do not 
possess a ‘stem-cell molecular signature’ but retain tumor-initiating ability in vivo.[23] This finding is 
important, as it contradicts the belief that especially these margin cells are highly tumorigenic. To 
what extent 5-ALA fluorescence correlates with contrast enhancement on iMRI (and therefore –indi-
rectly- with tumorigenicity of cells at the resection cavity, is currently being investigated (Senft et al, 
personal communication). The consequences of these findings on surgical strategy regarding EOTR 
remain to be seen. 
Implications for the future
Contrast enhancement on low-field strength iMRI at the border of the glioblastoma resection cavity 
has a high specificity but low sensitivity for high grade tumor. Absence of contrast enhancement is 
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unreliable to assess absence of tumor, and from that perspective the rationale for CRET becomes  
debatable. Especially in glioma surgery complication avoidance is of critical importance. Increasing 
sensitivity of tumor detection to increase EOTR may be undesirable if a correponding lower specific-
ity is associated with a higher incidence of (and/or more severe) postoperative neurological deficit. 
Furthermore, the definition of “tumor” is being discussed to include more than the contrast enhancing 
part,[32,31] and this may change the philosophy about maximizing tumor resection. There is class 1 
evidence that iMRI offers increased EOTR compared to a population of high grade glioma patients 
that were operated with or without conventional neuronavigation.[27] In a post-hoc exploratory  
analysis Senft et al. found no difference between both treatment arms in the control group, which is 
consistent with Willems et al. [34,27] Based on other literature there is, at best, class 2 evidence that 
iMRI-guided surgery is more effective than conventional neuronavigation-guided surgery in  
increasing EOTR, enhancing quality of life, or prolonging survival after glioblastoma resection.[10] 
Recently, the concept of ‘functional neuro-oncology’ was introduced by Duffau et al in low grade glio-
mas as a method to achieve optimal surgical resection guided by functional rather than by 
oncological-anatomical boundaries.[2,3] This approach does not suffer from imaging-related limita-
tions. If increased EOTR is associated with prolonged survival, the “functional neurooncology”  
approach might also be an alternative in high grade glioma surgery to determine resection borders 
compared to an imaging-based approach. 
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Our present study on glioblastomas shows that evident contrast enhancement (thick linear + tumor-
like) as detected on iMRI always reflects presence of high grade tumor and may thus be used as a 
parameter to increase EOTR. Furthermore, absence of tumor is always correlated with absence of 
such contrast enhancement. Unfortunately absence of contrast enhancement and presence of thin 
linear enhancement on iMRI is not useful for predicting absence of tumor. Obviously, diffuse gliomas 
including glioblastomas are neoplasms that cannot be cured surgically. An (arbitrary) minimally  
required resection threshold to improve survival, like the widely cited 98% as described by Lacroix et 
al[13] is debatable, and a valid method to measure this threshold still has to be 
established.[31,11,25,12,28,14] The use of 5-ALA or a “functional neurooncology” approach may be 
interesting alternatives for high grade glioma surgery using gadolinium-based contrast agents to  
increase EOTR safely. 
CONCLUSION
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RANDOMIZED 
TRIAL
Glioblastoma is an infiltrating malignant brain tumor. Standard treatment consists of surgery, radio-
therapy and chemotherapy, leading to a median survival of 14.6 months.[21] The role of surgery is 
still under debate, though mounting evidence suggests that increased extent of tumor resection 
(EOTR) is associated with prolonged overall survival.[13] 
Intraoperative MRI (iMRI) is a tool to maximize EOTR, but many reports on its efficacy suffer from 
methodological flaws.[5] A recently published randomized controlled trial (RCT) demonstrated that 
iMRI leads to increased EOTR in comparison to conventional surgery, comparable to the use of  
5-aminolaevulinic acid.[17] 
In this paper we present the results of an interim analysis of an international multicenter RCT that  
compares iMRI with conventional neuronavigation (cNN) for the neurosurgical treatment of  
glioblastoma. The objective is to assess whether iMRI-guided surgery leads to increased EOTR  
compared to cNN-guided surgery, and whether health-related quality of life (HRQOL) differs between 
these two approaches. We consulted the CONSORT (Consolidated Standards of Reporting Trials) 
2010 guidelines for reporting of this trial.[16] 
The study protocol is registered at ClinicalTrials.gov under number NCT00943007 and has been  
approved by the institutional ethics research boards of all participating centers. 
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Participants
We included 14 patients between March 2010 and July 2012 from all participating centers for the  
interim analysis of this RCT. Inclusion criteria were: supratentorial brain tumor – suspected to be  
glioblastoma on contrast enhanced diagnostic MRI, indication for gross total resection (GTR) of the 
tumor, age 18 years or older, WHO Performance Scale (WPS) 2 or better, ASA class 3 or better,  
adequate knowledge of the Dutch or French language, and informed consent. Exclusion criteria 
were: recurrent brain tumor, multiple brain tumor localizations, earlier skull radiotherapy, earlier  
chemotherapy for glioblastoma, chronic kidney disease or other renal function disorder, and a known 
MR-contrast allergy.
Sample size
To reduce the chance for type I errors (false positive) we used an alpha value of 0.05. To reduce the 
chance for type II errors (false negative) we used a beta value of 0.2 leading to a power of 0.8. We 
considered a 10% additional resection of the preoperative tumor volume as the minimal clinically rele-
vant difference, with an estimated standard deviation of approximately 12%.[12,15] This led to 23  
patients in each treatment group. To compensate for loss to follow-up we intended to include a total 
of 54 patients for the complete study.
Interventions
Experimental group
Within 72 hours before surgery, a standard neuronavigation MRI scan was made at 1.5 Tesla (T) or 3T 
according to the local neurooncology protocol (T1 1mm isovoxel after administration of a gadolinium- 
based contrast agent). Patients were operated in the iMRI operating room setup, using the Stealth 
Station neuronavigation system, Medtronic Polestar N20 (0.15T) moveable magnet and the  
Starshield® tent as a mobile Faraday cage for shielding radiofrequency noise (Medtronic Navigation, 
Louisville, CO). The head was fixed in a MR compatible head holder, and specific MR compatible  
anaesthesia equipment was used (monitor, ECG pads, thermometer). No other precautions needed 
to be taken because of iMRI, and regular instruments could be used. A first non-enhanced T1 iMRI 
scan was usually made before starting surgery, but this was not mandatory. When the neurosurgeon 
METHODS
79
considered glioblastoma resection to be complete, at least one intraoperative T1 7min 4mm scan 
was made after administration of contrast agent. In all but one case a so-called “double-dose” of  
contrast was used (0.2 mmol/kg). The neurosurgeon judged whether the scan demonstrated residual 
tumor, and decided either to continue resection if feasible and perform a new scan afterwards, or to 
finish the procedure after the intraoperative scan. If residual tumor was suspected, the “resection-
scan-cycle” was repeated until the neurosurgeon considered glioblastoma resection to be maximal. 
Within 48 hours after surgery, a regular control MRI scan was made including a contrast-enhanced 
T1 multi-planar reconstruction MR scan (1mm isovoxel).
Control group
The preoperative and postoperative imaging was the same as in the treatment group, only the  
surgical procedure differed. Patients were operated in a regular operating room setup using the 
Stealth Station neuronavigation system (Medtronic Navigation, Louisville, CO). The head was fixed in 
a standard Mayfield headclamp, and regular instruments were used. The surgery was finished at the 
point the neurosurgeon considered resection to be maximal. 
Outcomes
Primary endpoint
Residual tumor volume (RTV) percentage is used as the primary endpoint to assess EOTR. Pre- and 
postoperative tumor volume was calculated by segmenting the hyperintense area on contrast-
enhanced T1 MRI (including enclosed central necrosis) and subtracting the hyperintense area on  
native T1 MRI to compensate for blood in the resection cavity. Measurements were performed using 
OsiriX software (Pixmeo SARL, Bernex, Switzerland) on Mac OS X using a Wacom Bamboo pen 
mouse for contour drawing.  Postoperative tumor volume was divided by preoperative tumor volume 
to calculate the fraction of residual tumor volume. Multiplying the fraction with 100% provided the 
RTV. In formula:
RTV = (postoperative contrast enhancement / preoperative contrast enhancement) * 100%
Secondary endpoints
We recorded baseline demographic characteristics (sex, age, length, weight) and corticosteroid use 
on study entry. Complications were monitored on the case record form. WPS was scored one day  
before surgery, one day after surgery and before discharge from the hospital. We also recorded 
health-related quality of life (HRQOL). The patient was asked to complete the EORTC QLQ-C30 ques-
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tionnaire with the QLQ-BN20 brain cancer module, and the EuroQol EQ-5D questionnaires. The ques-
tionnaires were taken one day before surgery, before discharge and three months after surgery. Later 
we added “twelve months after surgery” to allow for a more long-term follow up as well. Raw scores 
were calculated and converted to standardized scores using a linear transformation. Overall survival 
was recorded for all patients. 
Randomization
Patients were randomized and allocated to either the cNN or iMRI group. Randomization was  
performed by the first author using TEN-ALEA software for randomization in clinical trials. This soft-
ware is provided by the Trans European Network (http://www.tenalea.com/) and maintenance for The 
Netherlands is performed by the Netherlands Cancer Institute (http://www.nki.nl/). No randomization 
blocks were used. The neurosurgeon could not be blinded for the procedure. We did not intend to 
blind the physicians on the ward, nor the patients. Volumetric assessment of pre- and postoperative 
tumor volume was performed by a single blinded researcher. 
Statistics
Descriptive statistics were used to express RTV, WPS and survival. Univariate analysis was used to 
express the difference between both treatment groups regarding RTV (Mann Whitney test), WPS 
(Mann Whitney test) and survival (Kaplan Meier analysis using a log rank test). After checking 
whether the residuals of the regression analysis were normally distributed, multivariate analysis was 
used to express the independent contributions on the primary endpoint of age, sex, preoperative tu-
mor volume, and histologically proven glioblastoma. For data entry and calculations, SPSS Statistics 
version 21 for Mac (IBM Corporation, Armonk, NY) was used. 
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Interim analysis
The decision to perform an interim analysis was approved by the institutional ethics research boards 
of the coordinating center. It was not part of the original research protocol, which we modified for  
several reasons. The main reason was that we estimated that our minimally required difference of 
10% would not be consistent with the actual results. Meanwhile iMRI did prolong surgery time by 1.5 
- 2 hours. Also surgery was hindered by device-related limitations in the iMRI group, like suboptimal 
ergonomics and intermittent malfunction of the ultrasonic aspirator (CUSA Excel Ultrasonic Surgical 
Aspirator; Integra Radionics, Burlington, MA, USA) due to magnetic interference. Further, we noticed 
that patient inclusion took significantly longer than expected based on a previous study.[6] This was 
mainly related to the indication for GTR as an inclusion criterion: patients in which preoperatively was 
decided to leave a small area of contrast enhancement untouched because of the vicinity of eloquent 
areas or to avoid significant opening of the ventricular system, were excluded.  
Baseline data
After randomization, 8 patients were assigned to the cNN group and 6 patients to the iMRI group.  
Participant flow is visualized in Figure 5.1. Mean age for the cNN group was 66 ± 8 years compared 
to 61 ± 5 years for the iMRI group. 11 patients were operated in the Netherlands and 3 in Belgium. In 
both treatment groups, one surgery was performed in the left hemisphere, all other surgeries were  
in the right hemisphere. Tumors were located in all lobes, except for in the iMRI group where no  
parietal tumors were included. Histopathology revealed glioblastoma in all patients except for two, 
having a metastasis: one in the cNN group and one in the iMRI group. All patients received radiother-
apy postoperatively, and most received chemotherapy with temozolomide. Further details are pro-
vided in Table 5.1.   
Outcomes
Outcomes were analysed for all patients according to an intention to treat principle. Imaging data 
were complete for all patients, but questionnaires contained some missing data (in particular HRQOL 
questionnaires). 
RESULTS
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Figure 5.1: Participant flow in the study
Tumor volumetry results are displayed in Table 5.2. The first three columns represent volumetry  
results for preoperative contrast-enhanced MRI, postoperative native MRI and postoperative 
contrast-enhanced MRI. The “post gado only” column represents postoperative contrast enhance-
ment (supposed to be residual tumor) and the last column displays rounded RTV values. Median RTV 
in the cNN group is 6.5% with an interquartile range of 2.5% - 14.75%. Median RTV in the iMRI group 
is 13% with an interquartile range of 3.75% - 27.75%. A Mann-Whitney test showed no statistically  
significant difference between these groups (p = 0.28). When both patients with a metastasis are  
excluded for further analysis, median RTV in the cNN group is 5% with an interquartile range of 2% - 
16% and median RTV in the iMRI group is 9% with an interquartile range of 3.5% - 33.5%. Also, for 
the glioblastoma population, a Mann Whitney test did not show a statistically significant difference  
between these groups (p = 0.43). Multivariate analysis does not reveal any significant influence of 
sex, age, preoperative tumor volume or histological diagnosis on RTV. 
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Table 5.1: Study demographics
Parameter Values cNN iMRI
Age (years)
Mean ± SD
Sex
Male
Female
Center
MUMC
CHUL
Atrium MC
Hemisphere
Left
Right
Main lobe
Frontal
Parietal
Temporal
Occipital
ASA class preoperative
1
2
WPS preoperative
0
1
2
WPS postoperative
1
2
3
66 ± 8 61 ± 5
4 3
4 3
4 5
2 1
2 0
1 1
7 5
1 1
3 0
3 3
1 2
6 3
2 3
1 0
6 5
1 1
1 1
2 2
5 3
Table 5.1 (continued): Study demographics
Parameter Values cNN iMRI
WPS discharge
0
1
2
Histological diagnosis
Glioblastoma
Metastasis
Postoperative 
radiotherapy Yes
No
Postoperative 
temozolomide Yes
No
2 1
4 3
1 2
7 5
1 1
8 6
0 0
5 4
3 2
Abbreviations: ASA = American Society of Anaesthesiologists, Atrium MC = Atrium Medical 
Center, CHUL = Centre Hospitalier Universitaire de Liège, cNN = conventional neuronavigation, 
iMRI = intraoperative MRI, MUMC = Maastricht University Medical Center, SD = Standard 
Deviation, WPS = WHO Performance Scale
Median preoperative WPS is 1 for both treatment groups, ranging from 0 to 2. Median WPS one day 
postoperatively is 3 in the cNN group and 2,5 in the iMRI group, ranging from 1 to 3 in both groups. 
Median WPS before discharge (approximately one week after surgery in both groups) is 1 in both 
groups, ranging from 0 to 2. For the latter, data for one patient in the cNN group are missing. Using a 
Mann-Whitney test, mean rank for the WPS before discharge is 6.3 in the cNN group and 7.8 in the 
iMRI group. The difference is not statistically significant (p = 0.53). 
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Median survival in the cNN group is 472 days, with an interquartile range of 244 - 619 days. Median 
survival in the iMRI group is 396 days, with an interquartile range of 191 - 599 days. The correspond-
ing log rank p-value is 0.81. When both patients with a metastasis are excluded for further analysis, 
median survival is 539 days in the cNN group and 396 days in the iMRI group, with a log rank p-value 
of 0.68. One glioblastoma patient in the cNN group opted for euthanasia eight months after surgery 
due to late disease-related complications. If this patient is excluded from the latter analysis, median 
survival remains unchanged, with a log rank p-value of 0.55. 
Figure 5.2a shows a Kaplan Meier curve that displays cumulative survival in time for both treatment 
groups, and figure 5.2b shows the same curve excluding patients with a metastasis. 
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Table 5.2: Tumor volumetry data
Patient Group Pre Gado Post Native Post Gado Post Gado Only RTV
RACL01 cNN 35.4 19.6 25.2 5.8 16
RACL02 iMRI 14.6 13.6 20.2 6.5 45
RACL03 cNN 11.0 12.7 13.3 0.5 5
RACM01 cNN 23.2 1.0 1.6 0.6 2
RACM02 iMRI 120.0 6.3 10.8 4.5 4
RACM03 cNN 28.6 1.2 3.5 2.3 8
RACM04 cNN 30.9 0.4 1.7 1.3 4
RACM05 cNN 12.6 6.6 8.0 1.4 11
RACM06 iMRI 99.3 16.3 38.4 22.0 22
RACM07 iMRI 23.8 24.8 28.7 4.0 17
RACM08 iMRI 43.9 14.9 16.3 1.5 3
RACM09 iMRI 77.4 53.0 60.2 7.2 9
RACM10 cNN 154.0 48.5 52.1 3.6 2
RACM11 cNN 39.9 22.4 29.8 7.5 19
Abbreviations: cNN = conventional neuronavigation, Gado = gadopentetate dimeglumine, iMRI = 
intraoperative MRI, RTV = Residual Tumor Volume percentage
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Figure 5.2a: Kaplan-Meier curve for all patients (n = 14)
Figure 5.2b: Kaplan-Meier curve for glioblastoma patients only (n = 12)
HRQOL scores are left out of this paper. Explorative data analysis does not show a clear advantage 
in HRQOL for either treatment group. After consultation of a health-technology assessment expert we 
decided to refrain from any further statistical analyses due to the small sample size.  
Adverse events
One patient from the iMRI group suffered from postoperative hemorrhage which led to prolonged  
hospital stay and cognitive impairment. No other adverse events or serious adverse events were  
reported.  
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Our study is the second randomized controlled trial on glioblastoma surgery using iMRI. This paper 
reports our results from an interim analysis of 14 patients. Volumetric assessment of the primary end-
point (RTV) does not show any advantage of iMRI-guided resection over cNN-guided resection: there 
is no statistical difference between both groups and mean RTV is higher in the iMRI group than in the 
cNN group. Clinical performance does not differ between both groups, and neither does survival in 
our population. Regarding HRQOL no firm conclusions could be drawn, although there is no clear  
tendency favoring one treatment group.  
Study inclusion has been halted based on the results of this interim analysis. The combination of the 
minimal difference between iMRI-based treatment and cNN-based treatment on the one hand and 
the slow inclusion rate on the other hand would lead to a much longer timeframe to achieve the statis-
tically significant results we initially aimed for. Based on the present interim analysis, however, we do 
not expect a different conclusion, and by the time that statistical significance would be reached, the 
technology used in this study is likely to be replaced by new devices. Therefore, the necessary  
additional investments associated with the investigated iMRI technology (mainly increased time con-
sumption in the operating theatre) does not seem justified in our opinion, and could even be consid-
ered as ethically inadequate.
Despite the small sample size, there is still a clear conclusion from this interim analysis, which differs 
from the conclusion of the only other iMRI RCT by Senft et al.[17] These authors concluded that iMRI-
guided glioblastoma resection leads to GTR in 96% of cases compared to 68% in the control group 
(p = 0.023). Their control group consisted of a mixed population of cNN-guided resection and  
resection without neuronavigation. A post hoc exploratory analysis did not demonstrate a significant 
difference between both arms in the control group. Their definition of GTR was a tumor volume of less 
than 0.175 cm3 detected by a contrast enhanced T1-weighted MRI, the same as used by Stummer et 
al.[21,20] The median postoperative volume of contrast enhancing tissue was 0 cm3 in the iMRI 
group and 0.03 cm3 in the control group. No further details on their volumetry methodology is  
provided in the article. To our opinion, the authors’ conclusion favoring iMRI-guided glioblastoma  
resection should be seen in the context of a minimal difference in postoperative tumor volume  
between both treatment groups. No significant difference exists in progression-free survival, and most 
importantly: there is a lack of a valid methodology for volumetric assessment of glioblastoma 
resection.[13,6,23] In our opinion, tumor volumes reported in the study of Senft are within the error lim-
its of tumor volumetry. Further, a clear definition of “tumor” is one of the challenges to be solved  
DISCUSSION
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besides improving accuracy of glioblastoma volumetry itself. Both these factors are key in defining a 
valid endpoint to measure glioblastoma resection. 
The widely cited study from Lacroix et al states that a minimum of 98% glioblastoma resection is 
needed for survival benefit.[5,11] In that study, the authors used a method by which they assessed 
intraobserver agreement, but not interobserver agreement.[18] The same comments applies to the 
study by Kuhnt et al.[16,9] Sanai et al reported a minimum of 78% glioblastoma resection needed for 
survival benefit.[12,14,15] These authors also used a volumetric approach based on manual  
segmentation of contrast-enhancing tissue on T1-weighted imaging, but did not describe any  
correction for hyperintense signal on native T1-weighted imaging, and did not report on intraobserver 
and interobserver agreement of their methodology. There is an ongoing discussion regarding an  
optimal approach to define and measure glioblastoma resection, and no consensus has been 
reached yet.[6,9,14,7,23,19] Therefore, in contrast to studies on radiotherapy and chemo-
therapy,[24,22] neurosurgical studies cannot yet benefit from a valid endpoint to measure  
glioblastoma resection, which limits external validity of individual study results. To minimize the error 
in respect to our own published data we decided to have tumor volumes measured by a single 
(blinded) observer. We previously described this approach to have high intraobserver agreement, but 
low interobserver agreement.[6] Nevertheless, this type of approach is still the most commonly used 
approach to tumor volumetry in neurosurgical studies.[12,9,10] 
A more fundamental discussion is to what extent further investments should be made to increase 
EOTR for glioblastoma surgery. Glioblastoma is a non-focal disease in which tumor cells can be 
found far beyond the contrast-enhancing area.[1,2,8,3] As long as there is no valid endpoint to  
quantify glioblastoma resection, no firm conclusions can be drawn regarding the added value of GTR 
(or CRET -complete resection of enhancing tumor- as described by Vogelbaum et al).[23] The  
minimal increase in patient survival after four decades of glioblastoma surgery (despite all sorts of 
technical equipment), in combination with no consensus on how to measure our results, may indicate 
that expanding technical innovation for glioblastoma resection should not have our highest priority at 
this moment.[4] 
Limitations
The main limitation of this study is the lack of a valid endpoint for glioblastoma volumetry, as  
discussed before. We used the best available tumor volume definition but, still, our volumetry results 
should not be considered as absolute values, but more as a tendency in which the exact quantifica-
tion can differ from the data provided in this article. Nevertheless, based on our previous study that 
analyzed intraobserver and interobserver agreement of glioblastoma volumetry, we are confident that 
the tendency reported in this article is a correct reflection of the results.[6] 
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Our interim analysis has a small sample size which limits statistical significance in our endpoints. In 
particular, differences between HRQOL in both treatments groups cannot be tested due to the small 
sample size aggravated by missing data. 
Finally it should be noted that our data result from an 0.15T iMRI system with its specific advantages 
and disadvantages. We do not expect different results on high-field strength systems, however, only 
because of a higher spatial resolution, but the use of other imaging modalities might lead to different 
conclusions. We also cannot make a valid comparison with 5-ALA guided surgery,[20] which might 
be an interesting control group for a future comparative study with iMRI. 
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This interim analysis of a RCT on iMRI-guided glioblastoma resection compared to cNN-guided  
glioblastoma resection does not show an advantage with respect to EOTR, clinical performance and 
overall survival for the iMRI group. Although the lack of a valid endpoint to measure glioblastoma  
resection prevents firm conclusions to be drawn, the added value of (ultra-low field strength) iMRI for 
this non-focal disease is to be debated seriously and does not seem to be cost-effective. Before 
evaluating new technological developments, research of the near future should primarily focus on  
developing a valid endpoint to compare surgical results, between different centers and with different 
technologies, as well as the assessment of survival benefits with increased EOTR.
CONCLUSION
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6GENERAL 
DISCUSSION
Intraoperative MRI
Intraoperative MRI (iMRI) was introduced to be able to navigate on updated images during neuro-
surgical procedures.[1] Conventional neuronavigation (cNN) is useful for planning the approach of a 
procedure, but is not capable of correcting for so-called “brain shift” that occurs intraoperatively.  
Although mathematical models have been applied on preoperative images to correct for brain 
shift,[2,23] they do not reflect a “live” view of the current situation. Depending on the sort of iMRI, this 
technology can offer this “live” view during surgery, but most sorts of iMRI require the surgical  
procedure to be stopped in order to acquire new images. The first system by General Electric,  
nicknamed the “double doughnut” for its physical appearance, offered 0.5 Tesla (T) field strength, 
and is today considered to be a low-field strength device. The surgeon was operating between the 
two vertically placed magnets (the “doughnuts”) which was ergonomically not the most comfortable 
position, but at least it did offer “live” (real-time) imaging.[1] Other systems as developed by e.g.  
Philips, Siemens and Medtronic do not allow real-time imaging but after a few minutes scanning time 
neuronavigation images can be updated and surgery can be continued.[6,24,26,8] Technology has 
evolved into two directions: high-field strength (1.5-3T) or low-field strength devices. High-field 
strength devices are more expensive (estimated cost around 4-5 million euro) compared to low-field 
strength devices (estimated cost around 1 million euro). Yearly maintenance is estimated to be ap-
proximately 10% of the acquisition cost. High-field devices offer better spatial resolution which results 
in better image quality, and they offer multimodality imaging (e.g. diffusion tensor imaging, magnetic 
resonance spectroscopy). In contrast, such devices are more heavy which places a higher demand 
on construction of the operating theatre, which is sometimes rebuilt in the basement of the hospital 
because the floor of the regular operating theatre cannot carry the weight. Also dedicated  
MR-compatible instruments are required in the operating room. To what extent these high-field 
strength devices limit surgical workflow is debatable: proponents of low-field strength imaging have 
been using this as a parameter in favor of low-field strength iMRI, but to our experience low-field 
strength iMRI suffers from workflow issues as well. The lower spatial resolution is not a practical limita-
tion when performing high grade glioma surgery, whereas performing low-grade glioma surgery with 
low-field strength iMRI can be more troublesome. On the ultra low-field strength iMRI device (0.15T) 
used for our research this is aggravated by the decreased signal-to-noise ratio of T2-weighted MRI 
compared to T1-weighted MRI. Pituitary surgery also takes a learning curve with respect to judging 
residual pituitary adenoma on contrast-enhanced images, and for this aspect the relatively low spatial 
resolution is a part of the challenge. Obviously the lower cost of (ultra) low-field strength iMRI is an im-
portant reason in favor of these devices. It is less troublesome to rebuild a regular operating room 
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into an iMRI suite, especially when local Faraday shielding is used (removing the need to build  
shielding into the walls of the room). It is hard to discuss cost-effectiveness only by taking surgical 
use of iMRI into account, because high-field strength devices are often integrated into a shared-room 
concept, in which the radiology department can use the (i)MRI device when it is not used for surgical 
procedures. The literature on cost-effectiveness for these devices is limited and inconclusive,  
although a recent study states that “there is no adequate justification for the widespread installation 
of low-field strength iMRI in its current development state“.[7,17] This conclusion is in line with other 
centers’ decisions to discontinue the use of iMRI, in particular (ultra) low-field strength iMRI (personal 
communication). 
Criticism
High grade glioma is one of the major indications for which iMRI is used. The introduction of this  
technology dates back before the class 1 evidence for 5-aminolevulinic acid (5-ALA),[25] which  
offers an alternative solution that is at least as effective as iMRI but does not require major  
investments upfront. [22] This thesis focuses on glioblastoma surgery with ultra low-field strength 
iMRI, and the opinions expressed are based on 8 years of personal experience with the device and 
communications with other users at various sites. 
Patient installation
During patient installation a compromise must be sought between optimal surgical access and a  
position which allows the head to fit between the magnets. The head clamp has a fixed size, which 
means that three pins have to be screwed into the skull by torque screw drivers. This is more cumber-
some and takes more time than a regular head clamp. Further it is important that the surgical site is 
approximately centered between the magnets for optimal image quality. This means that for tumors 
located near the skull base the magnet has to be “moved in” towards the feet, and collides with the 
shoulders (particularly in people who have a rather “short neck”). A little pressure on the shoulders 
during scanning (circa 15 minutes before pressure is released) is acceptable, but too much pressure 
should be avoided to prevent injury to the brachial plexus. Therefore it can be necessary to use a  
lateral position (in contrast to supine or prone), which prolongs setup time before surgery. 
Compatible equipment
For 0.15T iMRI regular surgical instruments can be used, although they can be attracted towards the 
magnet (causing frustration for the scrub nurse who tries to keep the instruments on her tables or-
dered). In the surgical field some interference caused by the magnet is noticable, but the only diffi-
culty during surgery has been the handling of the needle when suturing the wound. After surgery the 
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instruments had to be taken to a dedicated demagnetizer to avoid persistent magnetism in a next  
procedure (e.g. clipping an aneurysm, during which we discovered the phenomenon). The anaesthe-
sia monitor has to be MR-compatible  because the device will disturb signals on non-compatible 
monitors. Also MR-compatible thermometers and ECG stickers have to be used. Obviously the  
ventilation tube should not contain any metal: a reinforced tube once accidentally inserted did  
seriously decrease image quality, but fortunately did not harm the patient. Most of these issues  
happened in the first 1-2 years after installation, afterwards the same team was present during iMRI 
procedures which helped to avoid many of these. For the local Faraday shielding a dedicated floor 
plate is present in the operating room, and non-visible corrosion also has been known to reduce  
image quality. Changing the floor cleaning program and having it prepared before iMRI surgery  
eradicated this problem. 
Ergonomics
During the surgical procedure the iMRI system remains in place, although the magnets are lowered 
before surgery and raised before scanning. Even with the magnets in their lowest and most inward 
position, access to the patient has some restrictions. If the surgeon is in a standing position, there 
might be a need to bend slightly forward for a longer period because the magnets are in the way. If 
the surgeon is in a sitting position, the minimal table height required by the magnet might be too 
heigh to work comfortably. Further access to the patient is restricted by the magnet’s base. Another 
issue of concern is the lack of MR-compatible retractors. Surgeons who prefer to work with an  
halo-ring and retractors will notice that there is no MR-compatible alternative for the 0.15T iMRI de-
vice as used by our hospital. For some of the staff members this has been the most important reason 
why not to work with the iMRI device. 
Outcome measurement
When new technology is introduced into clinical care its added value towards standard treatment 
should be assessed. For (neuro)surgical devices that are intended to help increasing extent of tumor 
resection (EOTR) in a safe and reliable manner, EOTR should be assessed. The use of (progression-
free) survival as a study endpoint clearly has added value, but it is influenced by several postopera-
tive parameters which might be uncorrelated to the surgical procedure and associated outcome  
itself. Many neurosurgical studies that evaluate new technology with respect to EOTR use a  
volumetric approach towards tumor volume. In contrast to radiotherapy and chemotherapy which 
cause an approximately spherical decrease in tumor size, neurosurgical resection can cause a  
border of contrast-enhancing tissue to be visible on postoperative contrast-enhanced T1-weighted 
MRI. This cannot be assessed with the same tools that are used to assess effects of radiotherapy or 
chemotherapy (like the MacDonalds criteria, RECIST or the RANO advice).[16,27,29] Although  
volumetry can theoretically give a much more precise estimate of residual tumor volume, this  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approach cannot considered to be valid yet.[13,28] Intraobserver agreement is good for both pre-
operative and postoperative tumor volume, but interobserver agreement is only good for preoperative 
tumor volume. For postoperative tumor volume, and hence for residual tumor volume, interobserver 
agreement is low. If volumetry is to be chosen for outcome assessment, having all measurements 
done by one observer (blinded for treatment group) is currently the best option. This has the limitation 
that the numbers found cannot be interpreted as absolute numbers. To our opinion the “magic” 98% 
as a minimally required EOTR to improve survival, postulated by Lacroix et al.,[15] is not to be  
considered as any magic at all. Ten years later, new data were published by other groups with new 
percentages varying between 78% and 98%.[21,14] These studies used different methods of tumor 
delineation, performed by different observers, and none of these studies assessed interobserver 
agreement. 
Therefore no firm conclusions can be drawn by volumetry-based (i)MRI studies. [18,14,22] The  
randomized trial on this topic published by Senft et al describes a volumetry-based median  
difference of 0.03cm3 (p=0.0015) between the iMRI group and cNN group, which might be as well in 
the measurement margin. Besides it is doubtful whether this small difference is clinically relevant, 
knowing that there are plenty of tumor cells present outside the contrast-enhancing area in patients 
with glioblastoma. 
Correlation with histology
Kelly published data on serial sampling in stereotactic biopsies of untreated glioblastoma almost 
thirty years ago.[11] Since then it is well known that tumor cells are present outside the contrast  
enhancing area as visible on CT or MR imaging. Brain surgery inherently involves an iatrogenic  
damage to the blood-brain barrier and studies have been published describing residual contrast  
enhancement after repeated intraoperative contrast administration.[12,9] Therefore we systematically 
evaluated the correlation between contrast enhancement on T1-weighted iMRI and histopathological 
characteristics scored by two neurpathologists in a semi-quantitative manner. Essentially this study 
confirms that clearly visible contrast-enhancement is specific for tumor residual, but a small border of 
linear enhancement at the border of the resection cavity is less specific. This is in line with the conclu-
sion from Ekinci et al. based on preoperative and postoperative MRI.[5] If there is no visible contrast 
enhancement, chances are still around 50% (varying between 39%-70% depending on definitions of 
tumor and contrast enhancement) that there is tumor tissue present which exhibits high grade glioma 
features. Our study is limited to assessment of residual contrast enhancement (suspect for tumor)  
using iMRI. A recent study investigated the use of 5-ALA as a marker for representative stereotactic 
biopsy samples in several types of tumor, and found better values compared with our study for  
specificity (1.00) and sensitivity (0.69) in case of strong 5-ALA fluorescence.[30] Another study used 
5-ALA to differentiate between necrosis, (fluorescent) “tumor cells”, and (nonfluorescent) “margin 
cells”. They found that margin cells do not possess a ‘stem-cell molecular signature’ but retain tumor-
100
initiating ability in vivo.[20] This finding is important, as it contradicts the belief that especially these 
margin cells are particularly tumorigenic. To what extent 5-ALA fluorescence correlates with contrast 
enhancement on iMRI (and therefore – indirectly – with tumorigenicity of cells at the resection cavity, 
is being investigated (Senft et al., personal communication September 2012). The consequences of 
these findings on surgical strategy regarding EOTR remain to be seen. If we conclude that: (1) there 
are many tumor cells present outside the contrast enhancing area, (2) the small border of contrast  
enhancment at the edge of the resection cavity does not cleary correspond with tumor, and (3) the  
tumor cells that are present at the resection border are not more tumorigenic than other tumor cells, it 
is highly debatable to what extent a “gross total resection” or “complete resection of enhancing  
tumor” should be the surgical goal.  Also, there is well know non-overlap between contrast enhance-
ment on MRI and e.g. positron emitted tomography scans.[10,19] This illustrates another important 
issue when discussing glioblastoma treatment: we actually do not know well how to define “glioblas-
toma” based on imaging features. Without a clear definition of what our surgical target should be, it is 
difficult to discuss how to improve interobserver agreement of volumetry, and comparing different 
technical-surgical strategies with outcome becomes a daunting task. 
Added value
In our randomized trial we could not confirm the results from Senft et al. that indicate the added value 
of iMRI compared to cNN in patients with glioblastoma. We did not find less residual tumor volume in 
our iMRI group, nor did we find improved clinical performance, health-related quality of life or  
prolonged survival. To our opinion the added value of ultra low-field strength iMRI for glioblastoma 
should not be sought in maximizing resection by chasing after the small border of contrast enhance-
ment in the resection cavity. We also do not think that patients who show such an area of contrast  
enhancement on postoperative MRI should be reoperated. For glioblastoma surgery, 5-ALA might be 
a better approach when complete resection of enhancing tumor is the surgical goal. Clearly iMRI can 
have added value as a learning tool, allowing for direct feedback during the surgical procedure. 
Whether this justifies the high cost involved, is a different question which might have a negative  
answer in the current financial situation worldwide.  
Looking forward
A few steps are indicated for the future of glioblastoma surgery. First, we need to define what we con-
sider to be “tumor” eligible for surgical resection based on imaging techniques, and what techniques 
to use for this preoperative workup. Next, we need to develop and validate a primary endpoint that 
can be used in neurosurgical studies. Then we can start comparative studies and evaluate to what 
extent neurosurgical resection should be performed in order for the patient to benefit in quality of life 
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(an endpoint used too little) and in survival. More advanced health-technology assessment methodol-
ogy can be implemented for a balance between quality of life, survival and cost. The “functional 
neuro-oncology approach” with supramaximal resections as proposed by Duffau for low-grade 
glioma offers an alternative way to look at glioblastoma surgery.[3,4] Still, it is hard to evaluate without 
a clear endpoint and a valid way to measure this. For neurosurgical studies, it makes sense to use  
extent of tumor resection as the primary endpoint, because all sorts of postoperative strategies may 
vary and influence other endpoints. 
More philosophically, the role of EOTR in glioblastoma treatment is still debatable. If a preoperative 
tumor consists of 1011 cells, a gross total resection of 99% still leaves 109 cells behind. The cure for 
glioblastoma won’t be neurosurgical resection, and within this perspective all expensive technology 
that attempts to increase extent of tumor resection should be evaluated critically. 
This thesis does not evaluate other indications for ultra low-field strength iMRI and it does not  
evaluate other sorts of iMRI, in particular high-field strength devices. In particular the latter might be 
interesting for low-grade glioma surgery, although it has to be considered to place such an expensive 
device in one dedicated center to which patients are referred from a larger area. Still, to be able to 
evaluate this technology, the same concerns as expressed above for glioblastoma apply. 
For now, it can be perfectly justified to attempt complete resection of enhancing tumor in glioblas-
toma patients as long as they are not further harmed by the surgical procedure. However, the added 
value of ultra low-field strength iMRI does not seem to justify the cost, and it is not mandatory to  
resect that last small border of contrast enhancement  (as visible on T1-weighted imaging) at the  
border of the resection cavity . Neither does the latter justify a second-look procedure. And currently, 
any sort of absolute “magic” number for a minimally required extent of glioblastoma resection  
threshold that leads to a miraculous increase in survival can be considered a fairy tale instead of 
rock-solid science. 
The end. 
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7SUMMARY 
SAMENVATTING
Increased extent of tumor resection (EOTR) is associated with prolonged survival for glioblastoma  
patients. Conventional neuronavigation can be helpful in planning the surgical approach but can  
become unreliable during surgery due to “brain shift”, which is caused by tumor resection, loss of 
cerebrospinal fluid and brain tissue edema. Intraoperative MRI (iMRI) has been developed to correct 
for brain shift during surgery, and to offer the neurosurgeon updated images for neuronavigation. This 
should lead to increased EOTR without causing (additional) neurological deficit. This thesis evaluates 
the added value of the PoleStar N20 (0.15T) iMRI system with local Faraday shielding (using a “Star-
Shield”® tent) on glioblastoma surgery. 
The quality of the existing literature up to 2011 was limited due to several forms of bias, as explained 
in chapter 2. Of these, especially attribution bias was present in many studies. The old Latin proverb 
“post hoc ergo propter hoc” ends with a question mark: after which, so caused by? The conclusion 
that iMRI scanning demonstrated residual contrast enhancement (suspect to be tumor) at the mo-
ment the neurosurgeon “would have stopped resection” otherwise, is unreliable. The opportunity for 
intraoperative control seems to lead to a more conservative approach regarding tumor resection, 
which in return “causes” at least part of the residual enhancement. This question can only be solved 
by a randomized controlled trial (RCT). 
One of the challenges in reporting study outcome after tumor resection is to use a valid endpoint. 
There are many validated scales to report patient outcome. In contrast, technical outcome of neuro-
surgical treament is often expressed in residual tumor volume or resection percentage, which has not 
been validated yet. In chapter 3 we report the results for intraobserver and interobserver agreement 
for tumor volumetry (focused on glioblastoma). Both preoperative and postoperative tumor volumetry 
have high intraobserver agreement. But in contrast to preoperative tumor volumetry, postoperative  
tumor volumetry has low interobserver agreement. Therefore, residual tumor volume cannot be relia-
bly estimated. Still, if one observer is performing the measurements, a comparison between two 
groups can be made to demonstrate a trend in the data. Absolute numbers on performed or  
desirable EOTR cannot be provided yet, as a valid method for measurement is lacking. This is a  
serious limitation for comparative studies and for other studies that aim to describe a minimally  
required EOTR to improve survival. 
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Furthermore, in chapter 4 we report a study that examined the correlation between intraoperative  
contrast enhancement and histopathology. Iatrogenic damage to the blood-brain barrier during  
surgery might influence the contrast enhancement pattern of glioblastoma, compared to the pre-
operative situation. Intraoperative contrast enhancement has not systematically been examined to 
what extent it correlates to tumor presence. Still, this is considered as the gold standard during  
glioblastoma surgery. In our Borderzone Sampling trial we could quantify the correlation between  
contrast enhancement on iMRI and glioblastoma presence on histology. Clear contrast enhancement 
does correlate with tumor presence, but absence of contrast enhancement does not correlate with  
absence of tumor tissue in circa 50% of the cases. 
Up to date, two RCT’s on glioblastoma surgery have been performed using ultra low-field strength 
iMRI: one by Senft et al. (2011), and the study by our group (2013) which is reported in chapter 5. 
The Senft study is considered as class I evidence that iMRI-guided resection of glioblastoma leads to 
an increased percentage of gross total resection compared to conventional navigation-guided resec-
tion (96% versus 68% respectively). Critical in this context is the definition of gross total resection, 
which was defined as “less than 0.175 cm3 residual contrast enhancement”. Comparing secondary 
study endpoints of the Senft trial, the results are less convincing: median residual tumor volume in the 
iMRI-group was 0.00 cm3 whereas median residual tumor volume in the control group was 0.03 cm3. 
Also 6 months progression-free survival did not differ between both groups. In our study we could not 
demonstrate any statistically significant difference between the iMRI group and the control group  
using conventional neuronavigation with respect to EOTR, clinical performance or survival. 
The results of these RCTs should be seen in the light of two complicating factors: the absence of a 
valid method for postoperative tumor volumetry, and the limited correlation between contrast enhance-
ment on iMRI and tumor presence on histology. 
Therefore, we consider (ultra) low-field strength iMRI-guided glioblastoma surgery not to be signifi-
cantly more effective than standard treatment. The previously published literature has too many  
quality flaws to demonstrate the added value, EOTR cannot yet be measured in a reliable manner, 
imaging-based tumor definition is still troublesome with limited correlation between iMRI contrast  
enhancement and histology, and health-related quality of life does not show a trend towards a  
relevant difference. 
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For now, neither ultra low-field strength iMRI nor a minimally required 98% EOTR should be  
considered as a gold standard for glioblastoma surgery. For the future we need to develop a clear 
definition on what to consider as glioblastoma based on imaging characteristics and a valid method 
to measure EOTR in order to evaluate to what extent EOTR has added value in patient treatment. All 
this should be seen in the context of a surgically incurable disease, for which the principle “primum 
non nocere” (first do not harm) is as old as it is wise. 
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Een toegenomen mate van tumorresectie (MVTR) wordt in verband gebracht met een langere  
overleving voor patiënten met een glioblastoom. Standaard neuronavigatie kan helpen bij het  
planning van de operatieve benadering, maar kan tijdens een operatie onnauwkeurig worden ten 
gevolge van “hersenverplaatsing” veroorzaakt door tumorresectie, verlies van hersenvocht, en  
zwelling. Intraoperatieve MRI (iMRI) is ontwikkeld om tijdens de operatie te corrigeren voor deze  
hersenverplaatsing, en om de neurochirurg actuele beelden te geven voor neuronavigatie. Dit beoogt 
te zorgen voor een toegenomen MVTR zonder toegenomen neurologische uitval. Dit proefschrift  
onderzoekt de toegevoegde waarde van de PoleStar N20, een 0.15 Tesla iMRI systeem met lokale 
Faraday-kooi (in de vorm van de Starshield® tent) bij glioblastoomchirurgie. 
De kwaliteit van de bestaande literatuur tot 2011 was beperkt ten gevolge van verschillende soorten 
vertekening (bias), zoals uitgelegd in hoofdstuk 2. Van deze vormen van vertekening, met name  
zogeheten “attributie-bias” was aanwezig in veel studies. Het oud Latijns gezegde “post hoc ergo 
propter hoc” eindigt met een vraagteken: erna, dus erdoor? De conclusie dat iMRI scans 
restaankleuring toonden (verdacht voor tumorrest) op het moment dat de neurochirurg aangaf  
anders “gestopt te zijn met de operatie” is onbetrouwbaar. De mogelijkheid om tijdens de operatie te 
kunnen controleren of restaankleuring aanwezig was, lijkt te leiden tot een meer terughoudende  
benadering aangaande tumorresectie. Dit kan (een deel van) deze restaankleuring verklaren. Dit 
probleem kan alleen opgelost worden middels een gerandomiseerde studie. 
Een van de uitdagingen in het rapporteren van studie-uitkomsten na tumorresectie is het gebruik van 
een valide uitkomstmaat. Er zijn veel gevalideerde schalen beschikbaar om het functioneren van  
patiënten na een behandeling te meten. Echter als uitkomstmaat voor een technische handeling 
zoals een tumorresectie wordt vaak resttumorvolume of resectiepercentage gebruikt. Hiervoor is 
geen valide uitkomstmaat beschikbaar. In hoofdstuk 3 rapporteren wij de resultaten aangaande intra-
beoordelaar en interbeoordelaar overeenstemming voor tumor volumetrie (gericht op het glioblas-
toom). Zowel preoperatieve als postoperatieve tumorvolumetrie hebben hoge intraobserver overeen-
stemming. Echter in tegenstelling tot preoperatieve volumetrie heeft postoperatieve volumetrie een 
lage interobserver overeenstemming. Daarom kan resttumorvolume niet betrouwbaar beoordeeld  
worden. Op dit ogenblik is het wel mogelijk om een trend in de meetwaarden aan te tonen, maar niet 
om harde getallen te geven aangaande een verrichte danwel gewenste MVTR. Dit is een forse 
SAMENVATTING
110
beperking voor vergelijkende studies en voor studies die beogen een minimaal vereiste MVTR te 
beschrijven die moet leiden tot een betere overleving. 
In hoofdstuk 4 rapporteren we een studie die de relatie beschrijft tussen intraoperatieve  
contrastaankleuring en histopathologie. Iatrogene schade aan de bloed-hersenbarrière tijdens opera-
tie kan het aankleuringspatroon van het glioblastoom beïnvloeden, in vergelijking met de preopera-
tieve situatie. Er is nooit systematisch onderzoek in welke mate intraoperatieve contrastaankleuring 
overeenkomt met aanwezigheid van tumor. Nochtans wordt dit wel beschouwd als gouden standaard 
tijdens glioblastoomchirurgie. In onze Borderzone Sampling studie konden we een kwantitatief  
verband leggen tussen contrastaankleuring op iMRI en histopathologische aanwezigheid van |  
glioblastoom. Duidelijke contrastaankleuring komt overeen met aanwezigheid van tumor, echter  
afwezigheid van contrastaankleuring correleert niet met afwezigheid van tumor in circa 50% van de 
gevallen. 
Tot op heden zijn er twee gerandomiseerde studies verricht binnen de glioblastoomchirurgie die  
gebruik maken van ultra lage-veldsterkte iMRI: een door Senft et al. (2011) en onze studie (2013) die 
beschreven staat in hoofdstuk 5. De Senft-studie wordt beschouwd als klasse 1 bewijs dat iMRI-
geleide resectie van het glioblastoom leidt tot een toegenomen percentage van maximale resectie in 
vergelijking met standaard navigatie-geleide resectie (respectievelijk 96% en 68%). Belangrijk in dit 
verband is de definitie van “maximale resectie”, namelijk minder dan 0.175cm3 restaankleuring. De 
overige uitkomstmaten van de Senft-studie zijn niet overtuigend: mediaan resttumorvolume in de iMRI 
groep bedroeg 0.00cm3 terwijl mediaan resttumorvolume in de controlegroep 0.03cm3 bedroeg. 
Progressie-vrije overleving na 6 maanden verschilde niet tussen beide groepen. In onze studie  
konden we geen statistisch significant verschil aantonen tussen de iMRI groep en de controlegroep 
(standaard neuronavigatie) met betrekking tot MVTR, klinisch functioneren van de patiënten of over-
leving. 
De resultaten van deze gerandomiseerde studies moeten gezien worden in het licht van twee compli-
cerende factoren: de afwezigheid van een valide manier om postoperatief tumorvolume te meten, en 
de beperkte relatie tussen contrastaankleuring op iMRI en histopathologische aanwezigheid van  
tumor. 
Om deze redenen beschouwen wij (ultra) lage-veldsterkte iMRI-geleide resectie van het glioblastoom 
niet als bewezen effectiever dan de standaardbehandeling. De voordien gepubliceerde literatuur 
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kent teveel methodologische beperkingen om de toegevoegde waarde aan te tonen, MVTR kan niet 
betrouwbaar gemeten worden, de definitie van tumor op basis van beeldvorming is onvoldoende 
duidelijk met een beperkte relatie tussen contrastaankleuring en histopathologie, en gezondheids-
gerelateerde kwaliteit van leven toont geen duidelijke trend richting een relevant verschil. 
Voor nu, noch ultra lage-veldsterkte iMRI noch een minimaal vereiste 98% MVTR dienen beschouwd 
te worden als een gouden standaard voor glioblastoomchirurgie. Voor de toekomst moeten we een 
duidelijke definitie ontwikkelen van wat te beschouwen als tumor op basis van beeldvorming en een 
valide manier om MVTR te meten, om te kunnen beoordelen in welke mate MVTR toegevoegde 
waarde heeft in de behandeling van patiënten met een glioblastoom. Al dit moet gezien worden in de 
context van een chirurgisch niet te genezen ziekte, waarbij het principe “primum non nocere” (in de 
eerste plaats, doe geen kwaad) even oud is als wijs. 
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Dit proefschrift is tot stand gekomen door de bijdragen van veel verschillende mensen, direct danwel 
indirect. Een aantal van hen wil ik met name bedanken, vanwege hun concrete bijdragen en hun  
inspirerende aanwezigheid. 
Hoewel mijn onderzoek technologisch van aard is, staat de techniek in dienst van de arts en uiteinde-
lijk de patiënt. Aan de deelnemers en familie van de Borderzone Sampling studie en de  
gerandomiseerde studie ben ik dan ook zeer veel dank verschuldigd voor het gestelde vertrouwen, 
en de medewerking aan de studies. 
Prof.dr. J.J. van Overbeeke, beste Koo, onder jouw supervisie heb ik zowel mijn promotie-onderzoek 
als opleiding tot neurochirurg voltooid. In beide ervaar ik jouw “walk your talk” gehalte als een groot 
voorbeeld, en ben je me met raad en daad tot steun geweest. Voorts ben ik via jou in contact  
gekomen met een van je eigen opleiders, professor James Ausman, waar ik ook veel aan te danken 
heb. Wat betreft de technologische kant van mijn eigen carrière ben ik je op het juiste moment tegen-
gekomen. Je kritische vragen hebben me geholpen mijn focus helder te krijgen, en daar heb ik  
vervolgens de vruchten van mogen plukken. 
Dr. H. van Santbrink, beste Henk, in je eigen proefschrift beschrijf je een haat-liefdeverhouding te 
hebben gehad met jouw copromotor. Die ervaring deel ik absoluut niet. Weliswaar hoor ik innerlijk 
jouw stem “punt” zeggen als ik na vier regels tekst de achtste komma toevoeg om een zoveelste 
bijzin te produceren, en die punt is dan hard nodig. Verder herinner ik me onze samenwerking vooral 
als gemoedelijk, gaandeweg kameraadschappelijk, waarbij je me op cruciale momenten op de juiste 
manier wist te motiveren om datgene te doen wat nodig was. Ik ben dankbaar voor je begeleiding als 
opleider en copromotor, maar meer nog voor je begeleiding als mens.
Prof.dr. E.A.M. Beuls, onder uw begeleiding heb ik mijn eerste stappen gezet in de neurochirurgie. Ik 
herinner mij als gisteren mijn sollicitatiegesprek, waarin u tegen de aanwezige (toen nog geheten) 
drs. Vandewalle sprak: “Dit is Pieter, die weet veel van computers en zo iemand hebben wij nodig”. 
Dank voor het vertrouwen waarmee u mij een opleidingsplaats tot neurochirurg hebt aangeboden. 
AAN IEDEREEN, MET NAME...
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Uw motto was altijd “Ge moet de mogelijkheden zien” en dat motto heb ik met genoegen overge-
nomen in mijn eigen ontwikkeling. 
Dr. G.H.J.J. Spincemaille, beste Geert, samen met professor Beuls heb jij ervoor gezorgd dat het aca-
demisch ziekenhuis in Maastricht als eerste (en tot nu toe enige) ziekenhuis in het land de beschik-
king kreeg over een intraoperatieve MRI. Onder jouw begeleiding heb ik niet alleen kunnen starten 
met mijn promotie-onderzoek, maar ook de samenwerking met de Technische Universiteit Eindhoven 
(TU/e) kunnen uitbouwen, alsmede de samenwerking met Medtronic Navigation. Je eigen proefschrift 
sloot je af met de woorden: “De toekomst is aan hen die durven”, en ook dat motto heb ik graag  
overgenomen. 
Prof.dr.ir. B. ter Haar Romeny, beste Bart, dank voor de prettige samenwerking met de afdeling  
Biomedical Image Analysis (BMIA) van de TU/e. Het was voor mij een nieuwe wereld, waar je me 
snel in hebt laten thuis voelen. Het was een verrijking om de wetenschap mee te beleven door 
technische ogen, en soms een uitdaging om de aansluiting bij het klinisch denken te laten ontstaan. 
Ik kijk terug op een leuke en leerzame tijd, en wens jou en je vrouw het allerbeste voor je emeritaat, 
en bovenal een goede gezondheid!
Bram Platel, ik heb veel plezier beleefd aan onze samenwerking in de BMIA context. Of het gesprek 
nu ging over non-linear image transformations (op een Mac, uiteraard) of het unlocken van de eerste 
iPhone: als Apple adepten begrepen wij elkaar uitstekend! Het UMCN mag zich gelukkig prijzen met 
jou als aanvulling…
MSc en PhD studenten van de BMIA groep (Ralph, Ellen, Joost, Annet), dank voor de leuke 
samenwerking. Jullie hebben me versteld doen staan van wat jullie in een korte periode kunnen 
bereiken, onder begeleiding van Bart, Bram, en Anna Vilanova, en ik hoop in de toekomst een soort-
gelijke samenwerking opnieuw te mogen beleven. 
Erwin Cornips, al vroegtijdig heb jij de iMRI in Maastricht omarmd als hulpmiddel voor de  
hypofysechirurgie, en kinderoncologie. Dat heeft een waardevolle bijdrage geleverd aan de kennis 
en ervaring die we met het apparaat hebben opgedaan, en geleid tot meerdere gezamenlijke artike-
len. En congresbijdragen… onder de Eiffeltoren kon ik je rennend nog bijhouden, tegenwoordig loop 
je kilometertijden waar ik alleen jaloers op kan zijn. 
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Olaf Schijns en Mariël ter Laak-Poort, jullie hebben het merendeel van de iMRI-geleide operaties uit-
gevoerd waarbij ik zowel beter heb leren opereren, als ook de data voor mijn onderzoek kon verzame-
len. Dit alles in een prettige en ontspannen sfeer, ook als de opstartprocedure voor de ingreep weer 
eens langer nodig had dan verwacht in verband met een technisch probleem. Dank jullie wel!
Onno Teernstra, dank je dat je in Heerlen onderzoekscoördinator hebt willen zijn voor de RACING 
studie. Je whiteboard stond toen al vol met studies waaraan je deelnam, ik ben blij dat deze er nog 
bij mocht. Een tip voor als dat whiteboard nog voller wordt: je kunt er nog eentje aan het plafond van 
je kamer hangen. Proefondervindelijk hebben we reeds gezien dat andere voorwerpen daar ook aan 
blijven kleven. 
Professeur Martin, cher Didier, nous nous sommes rencontrés pendant une conférence de Medtronic, 
et il n’y a pas beaucoup des personnes qui savent que la collaboration entre Maastricht et Liège a 
commencé avec nous deux qui ont dansé le flamengo (heureusement il y avait des autres personnes 
aussi à cette soirée organisé par Medtronic). Tu m’as expliqué qu’on ne subit pas un opération, mais 
on bénéficie d’un opération (mais qu’au contraire, on subit une coloscopie, tu as dit). Je te remercie 
pour l’atmosphère toujours amicale quand je venais à Liège en salle d’opération pour la recherche. 
Merci beaucoup!
Dr. Scholtes, cher Felix, notre collaboration est vraiment amicale, tu es plus un ami qu’un collègue. 
Ensemble, nous avons réussi à concrétiser l’étude randomisée de commencer, et je suis heureux que 
tu aies décidé de travailler à Liège aussi après ta formation. J’espère que notre collaboration peut 
continuer pour d’autres recherches dans l’avenir! 
Alle andere stafleden neurochirurgie van onze vakgroep, dank dat jullie aan mij en mijn studies dach-
ten wanneer jullie een patiënt met een (vermoedelijk) glioblastoom gepresenteerd kregen, en een  
operatie overwogen. En –buiten mijn onderzoek om- bovenal dank voor jullie bijdragen aan mijn 
opleiding tot neurochirurg en collegiale houding. 
Pieter Wesseling en Martin Lammens, jullie hebben een grote bijdrage geleverd aan de Borderzone 
Sampling studie. Na een kenninsmakingsgesprek was jullie duidelijk dat een gestandaardiseerde 
manier van dataverzameling nodig was. Jullie hebben dit zelf opgezet en uitgevoerd, waarvoor grote 
dank.
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Linda Jacobi, je weet inmiddels wat tumor-volumetrie inhoudt. En met name de hoeveelheid tijd die 
daarmee gemoeid is. Dank je dat je die toch hebt willen vrijmaken, het heeft een grote meerwaarde 
gehad voor mijn onderzoek.
Collega arts-assistenten en Luc, dank voor de leuke sfeer en onderlinge collegialiteit, als ook de 
ruimte om voor mijn onderzoek de intraoperatieve MRI-operaties te kunnen bijwonen. Het voelt als 
een voorrecht om te werken binnen een groep die elkaar onderling steunt, en waar altijd flexibel geke-
ken wordt naar mogelijkheden in plaats van onmogelijkheden. 
Neuro-oncologieverpleegkundigen, Hilly en Natasja, dank voor de hulp met het completeren van de 
data!
Medewerkers van de operatiekamer, jullie hebben mijn onderzoek mede mogelijk gemaakt. De intro-
ductie van “dat ding” ging zeker niet zonder problemen, en mede dankzij jullie open houding hebben 
we onze kennis kunnen uitbouwen, en dit onderzoek kunnen verrichten.
Planners van de operatiekamer, jullie zijn ons immer terwille geweest als er weer een deelnemer aan 
een van onze studies was waarvoor intraoperatieve MRI nodig was. Neurooncologie kent geen  
electief karakter, en ons onderzoek nam extra OK-tijd in beslag. Dank dat jullie deze ruimte herhaalde-
lijk voor ons gecreëerd hebben. 
Poetsploeg van de operatiekamer, jullie bijdrage aan dit onderzoek is makkelijk te onderschatten. We 
ontdekten al snel dat onze local Faraday shielding erg gevoelig was voor ruis, en dat goed contact 
met de vloerplaat essentieel was. Dat deze een speciale voorbehandeling vereist, hebben we gaan-
deweg ondervonden. Dat er aparte borden “plaat poetsen” op OK 15 bestonden, onderstreept dit 
belang. Dank jullie voor alle hulp!
Medtronic Navigation staff, in particular Serge, Zvi, Hans, Jacob and Jan, thanks for your help 
throughout the years, the unrestricted grants with which you have supported our research, and the 
user meetings which have been both informative and enjoyable. 
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Martien Limburg, je sloot mijn stagejaar neurologie af met de conclusie dat ik een “hoog associatief 
denkpatroon” heb. Er heeft me nog nooit iemand zo constructief uitgelegd dat ik (soms) van de hak 
op de tak kan springen en onnavolgbaar ben. Je hebt me leren focussen op de andere kant van de 
medaille, waarvoor grote dank. En mindmaps gebruik ik nog steeds!
Wim Weber, hoewel we elkaar niet meer vaak tegenkomen, moet ik toch vaak terugdenken aan je 
kledingadviezen tijdens mijn stagejaar neurologie. Als ik straks mijn proefschrift verdedig, en aan-
treed met kraag, donkere sokken en gepoetste schoenen, zal ik denken: zo zou Pim Wim het gewild 
hebben…
Fons Kessels, professor Don Alfonso, dank voor je humor, en zeker ook dank voor je geduld. Ik  
realiseer me dat je het in het begin nodig hebt gehad! Ik ben blij dat je ook na je pensionering nog 
wat tijd wilde vrijmaken om me te helpen met het afronden van dit boekje. 
Rob en Hannie, als ik mijn schoonouders zelf had mogen uitzoeken, had ik jullie ook gekozen. Dank 
jullie voor het tweede thuis, de warmte en liefde, de geborgenheid. Ik hoop nog veel mooie momen-
ten met jullie te beleven! 
Rick, Christel, Tim en Roslynn, het voelt goed om jullie als schoonbroers en –zussen te hebben. Of 
het nu gaat om het volgen van een huwelijksdag via WhatsApp danwel twee beschaafde mensen in 
onze woonkamer te zien veranderen in holbewoners, alles kan… Dank!
Nard, je bent mijn enig(st)e broer, en een mens waar ik veel respect voor heb. Ik kijk met een glim-
lach terug op de jaren waarin we gezamenlijk zijn opgegroeid, en waarin jouw wetenschappelijk  
inzicht het mijne reeds overtrof: een emmer blijkt veel sneller gevuld te zijn met bessen, als je eerst 
op de bodem een dikke laag blaadjes legt! Op de middelbare school had je er wel eens moeite mee 
om “de broer van” te zijn, en begrijpelijk. Nu ben ik “de broer van”. Je bent me voorgegaan met jouw 
promotie-onderzoek, dat dermate veel voor mij onbegrijpelijke terminologie bevat dat ik het anderen 
nog steeds uitleg als “iets met eiwitten en veroudering”. Lamines, leg je die niet op de vloer in je 
woonkamer? Sta me toe jou mijn onderzoek kort uit te leggen in de terminologie waarmee jij mijn vak 
beschrijft: je neemt een pleister (de operatie) en plakt die op de wond (het glioblastoma). De vraag is 
of de pleister beter werkt als je een foto maakt tijdens het plakken, dan wanneer je dat alleen tevoren 
doet. Capice?
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Pap, zonder jou had ik niet gestaan waar ik nu sta. Sterker nog, zonder jou had ik helemaal nergens 
gestaan (…). Je hebt me de ruimte gegeven voor mijn toekomstkeuzen, en de ruimte gegeven om 
me computers eigen te maken op een manier waar ik veel voordeel van heb ondervonden. Tegelijk 
was er de ruimte buiten, een ruimte die ik nog steeds erg waardeer. De laatste jaren ontdek ik steeds 
meer in welke mate we op elkaar lijken, en kan ik het liedje van Stef Bos niet meer horen zonder licht 
glinsterende ogen te krijgen. Papa, ik hou steeds meer van jou…
Mam, je bent altijd de steunpilaar in het gezin geweest, je hebt er als moeder altijd gestaan voor 
Nard en mij. Je was er voor ons als het goed ging, en je was er voor ons als het niet goed ging. Je 
was er eigenlijk altijd voor ons, als we je nodig hadden. Je hebt ons gesteund om te groeien in  
datgene wat we goed konden, en je hebt ons geholpen om te groeien in datgene wat we niet goed 
konden. Je hebt ons getoond wat onvoorwaardelijke liefde is. Ik hou van jou, en hoewel ik de  
boodschap van het liedje “Blief bie de mam” op mijn eigen manier wil invullen, vind ik de afsluiting 
van het nummer eenvoudigweg prachtig krachtig… Mama, bedankt!
Mandy, jij bent de reden waarom ik in liefde geloof. Je houdt me in balans, je hebt me laten groeien 
als mens, en je hebt me meer rust in mijn leven gegeven. Bij jou kan ik mezelf zijn, en mijn eigen 
accu opladen. Ik ben blij met je steun, en heel dankbaar voor je liefde. Ik hou veel van je, en wil 
graag met jou oud worden. From this moment on…
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Pieter Kubben is geboren op zondag 30 april 1978 in Geleen. De peuterjaren werden doorgebracht 
in Moorveld. Nadien verhuisde het gezin naar Munstergeleen, alwaar de eerste schooljaren doorge-
bracht werden bij basisschool Aon de Bronkboum. De schoolcarrière werd vanaf 1990 vervolgd aan 
het gymnasium bij scholengemeenschap Sint Michiel te Geleen, met een beta-richting in de laatste 
twee schooljaren. Na een gunstige loting werd in 1996 gestart met de studie geneeskunde aan de 
Universiteit Maastricht. Al in het tweede studiejaar bleek de interesse voor neurowetenschappen, 
welke versterkt werd door een tweetal keuzeblokken in die richting. Deze leidden tot de eeste stapjes 
op wetenschappelijk terrein, zowel bij de neurologie (met dr. A. Twijnstra) als bij de neurochirurgie 
(met drs. E. Kurt en dr. M. van Kroonenburgh). Tijdens de co-schappen werd de voorkeur voor een 
verdere carrière duidelijk: neurochirurgie. Na een positief kennismakings- en sollicitatiegesprek met 
prof.dr. E. Beuls en (toen nog) drs. Vandewalle startte de ANIOS periode in 2003. Vanaf 2006 werd 
dit omgezet in een AGIKO-constructie in samenwerking met de technische universiteit Eindhoven, 
met onderzoeksbegeleiding van dr. G. Spincemaille en nadien dr. H. van Santbrink. Vanaf 2008 werd 
het klinisch opleiderschap overgenomen door prof.dr. J. van Overbeeke voor Maastricht en dr. H. van 
Santbrink voor Heerlen. Gedurende dezelfde periode werd het overige ICT-aandachtsgebied  
uitgebouwd, eerst in samenwerking met prof.dr. A. Scherpbier en dr. H. Hoogland, nadien in 
samenwerking met prof.dr. J. Ausman (Surgical Neurology International). In 2012 volgde een  
onderzoeksstage naar Brain Computer Interfaces aan de UCLA (Los Angeles, California) in 
samenwerking met dr. N. Pouratian. Vanaf 1 januari 2014 is Pieter zich als neurochirurg in het 
MUMC+ verder  aan het verdiepen in de functionele neurochirurgie, en daarnaast levert hij een  
structurele bijdrage aan de informatietechnologie in het ziekenhuis. 
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Personal website
http://www.kubben.nl
Personal weblog
http://DigitalNeurosurgeon.com (= dign.eu )
Associate editor-in-chief and IT editor
http://surgicalneurologyint.com 
Dutch Society for Neurosurgery
http://nvvn.org
Blog at Artsennet.nl
http://www.artsennet.nl/opinie/artsen-blogs/Pieter-Kubben.htm 
Dutch Society for Neurosurgical Residents (until 2013)
http://nvna.info
Pilot project for online collaboration with mobile output (until 2008)
http://neurowiki.com
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One of six “Need to Know Apps for Healthcare professionals in 2013” (Dec 2013)
Editor’s pick award  “Best Windows 8 Apps” (Dec 2013)
Listed as the #1 app for neurosurgery in CNS Quarterly magazine (Fall 2013)
Website/app of the month. Neurosurgery’s Brain School, University of Toronto (Sep 2013)
Radio interview for BNR on eHealth (Jun 2013, Dutch)
Magazine interview for Zorgvisie (Jun 2013, Dutch)
Magazine interview for VVAA / Arts & Auto (May 2013, Dutch)
Newspaper interview for Financieel Dagblad (Mar 2013, Dutch)
Listed as a Top Ten “Best Top Free Medical Apps” (Mar 2013)
Listed as one of the “indispensable tech-tools for nurses” (Mar 2013)
Cover article on “Doctor App” in newspaper De Limburger (Jan 2013, Dutch)
Article in CNS Quarterly magazine – Winter 2013 (Jan 2013)
Named one of the “Top Ten Internet-Smart Doctors in the WORLD” (Dec 2012)
Honorable Mention in iPad Top Apps series on iMedicalApps.com (Jun 2012)
Article in the British Journal of Neurosurgery (Jun 2011)
Article in the IBTA‘s Brain Tumour, World Edition 2011
Presentation on TEDxMaastricht (Apr 2011; watch on YouTube)
Interview in Mozaiek, Atrium MC magazine (Apr 2011, Dutch)
Back cover on MediRisk magazine “Alert” (Mar 2011, Dutch)
News item on Neurosurgic.com (Mar 2011)
Article on iMedicalApps.com (Mar 2011)
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Interview in Medisch Contact magazine (Mar 2011, Dutch; see cover)
Interview Dagblad De Limburger / Limburgs Dagblad (Mar 2011, Dutch)
Article in MacFan magazine (Feb 2011, Dutch); “neuroloog” is an error…
Article in Observant (2011, Dutch)
Press release Maastricht University Medical Center (2011)
Interview Nederlands Tijdschrift voor Geneeskunde (2011, Dutch)
Article on Reach Out Pro (2010)
Top 20 Free iPhone Medical Apps For Health Care Professionals (2010)
Article in Arts & Auto, VVAA magazine (2010, Dutch)
Interview American Medical Association (2010)
33 iPhone Apps Every Healthcare Professional Needs  (2010)
Free iPhone medical apps that every doctor can use (on KevinMD.com, 2010)
Top 10 Free iPhone Medical Apps for Health care Professionals (2010)
Interview Observant (2010, Dutch)
Interview iMedicalApps.com (by @OrthoOnc, 2010)
Television interview on L1 about intraoperative MRI. 17 March 2010. (watch video on YouTube)
“Prijs voor medicus met ICT-genen”. Automatiseringsgids. (2004, Dutch)
“Arts wint internationale prijs met ‘elektronisch spiekbriefje’”. MedNet. (2004, Dutch)
“Prijs voor beslissingsondersteunende software voor medisch onderwijs”. (2004, Dutch)
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NeuroMind
the world’s #1 ranked neurosurgical app and three times listed in the widely cited “Top Apps” on 
iMedicalApps.com. Available for iPhone, iPad, Android and Windows 8.
SLIC
an app for iPhone and iPad on subaxial cervical spine injury. It offers an evidence-based decision 
supporting system on surgical indications and technical approaches.
 
Safe Surgery
a dedicated iPhone implementation of the WHO Safe Surgery checklist. This digital version includes 
a progress indicator and feedback after each of the three check moments.
SNI Mobile
an app for iPhone, iPad and Android for the open access journal Surgical Neurology International.
OrthoRef
an app with more than 100 orthopedic scores and classification systems for clinical practice.
AIOS app
a project in collaboration with SoFoKleS, De Jonge Orde, LVAG and Modernisering Medische  
Vervolgopleidingen.
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Pieter Kubben can be contacted by various digital channels.
E-mail
pieter@kubben.nl 
Twitter
http://twitter.com/DigNeurosurgeon 
Facebook
http://www.facebook.com/pkubben 
LinkedIn
http://www.linkedin.com/pub/pieter-kubben/b/263/365 
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